Single-Cell Dissection of the Breast Cancer Microenvironment Reveals Distinct Genomic, Cellular, and Intercellular Communication Landscapes
This single-cell RNA-sequencing analysis comprehensively characterizes breast tissue, contrasting normal with primary tumor conditions. We identify widespread aneuploidy in tumor epithelial cells, profound remodeling of the tumor microenvironment with activated fibroblasts and altered immune cell populations, and distinct cell-cell interaction networks. These findings reveal critical genomic instability, metabolic reprogramming, and intercellular signaling hubs that drive breast cancer progression.
Contents
- Dataset overview
- UMAP Visualization of Single-Cell RNA-seq Data by Condition, Sample, Cell Type, and Ploidy in Breast Tissue
- UMAP Visualization of Key Cell Type Markers and Minor Cell Type Annotations
- Overall Celltype_subset Marker Expression Profile
- Copy Number Variation Analysis in Tumor-Origin and Unassigned Cells Grouped by Sample
- CNV-based UMAP Visualization of Single-Cell RNA-seq Data
- Minor Cell Type Population Analysis in Breast Tissue: Normal vs. Primary Tumor
- T Cell and Innate Lymphoid Cell Subpopulation Analysis in Breast Cancer
- Macrophage Subset Population Analysis in Breast Tissue: Normal vs. Primary Tumor
- Analysis of T Cell Subset Proportions in Breast Tissue
- Ploidy Population Analysis of Epithelial and Unassigned Cells in Breast Tissue
- Cell-Cell Interaction Patterns in Primary Breast Tumors
- Primary Breast Tumor Cell-Cell Interaction Analysis
- Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Related Genes in Breast Tissue
- Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer
- Epithelial Cell Condition-Specific Surfaceome Markers in Breast Tissue
- Macrophage Condition-Specific Surfaceome Markers in Breast Tissue
- Fibroblast Condition-Specific Surfaceome Markers in Breast Tissue
- Differential Expression of Cell Cycle-Related Gene YWHAZ in Breast Epithelial Cells
- Gene Ontology (GSA) Analysis of Epithelial Cells in Breast Tissue
- Gene Set Enrichment Analysis (GSEA) of Breast Tissue Cell Types in Primary Tumor vs. Normal Conditions
- Discussion
- Query List
0. Dataset overview
Dataset Summary
Total Cells: 88,707 cells
Total Genes: 25,535 genes
Species: Human
Tissue: Breast
Conditions: primary_tumor, normal
- Cell Type Annotations: Available at major, minor, and subset levels (e.g., Epithelial cell, T cell CD8+, Luminal epithelial cell).
- Ploidy Information: Cells are classified as 'Aneuploid' or 'Diploid' (obs['ploidy_dec']).
- Precomputed Analyses: Includes Cell-Cell Interaction (CCI), Differential Expression Gene (DEG), Gene Set Enrichment Analysis (GSEA), and Gene Ontology (GO/GSA) results.
- Copy Number Variation (CNV): CNV estimates (obsm['X_cnv']) are available.
- Tumor Origin Celltype: Epithelial cell is identified as the tumor origin cell type.
- Reference Condition: 'normal' is used as the reference for DEG_vs_ref, GSEA_vs_ref, and GSA_vs_ref_up analyses.
1. UMAP Visualization of Single-Cell RNA-seq Data by Condition, Sample, Cell Type, and Ploidy in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis provides a comprehensive visualization of single-cell RNA-sequencing data from breast tissue on a Uniform Manifold Approximation and Projection (UMAP) embedding. The UMAP plots are colored by various cellular and sample-specific attributes: disease condition (primary_tumor vs. normal), individual sample origin, major cell type, minor cell type, inferred ploidy status, and detailed cell type subsets. These visualizations are crucial for assessing data quality, cell type annotation fidelity, potential batch effects, and identifying biologically meaningful patterns related to disease state and cellular characteristics.
Visual Summary
Condition and Sample Distribution
- Condition UMAP: The UMAP shows a clear separation and distinct patterns between cells from normal (maroon) and primary_tumor (purple) conditions. While some regions show intermingling, indicating shared cell populations or states, several large clusters are predominantly composed of primary_tumor cells, particularly on the right side of the embedding. Conversely, other clusters are largely dominated by normal cells, suggesting significant transcriptomic differences driven by the disease state.
- Sample UMAP: Cells from different samples (patients) are largely intermixed across the major clusters, rather than forming distinct patient-specific groups. This indicates a good level of integration and minimal strong batch effects, implying that the observed cell clustering primarily reflects biological variation rather than technical differences between samples.
Cell Type Hierarchy
- celltype_major UMAP: Major cell types such as Epithelial cells (orange/light orange), T cells (cyan), Myeloid cells (light green), Endothelial cells (red), and Stromal cells (dark green) form well-defined and distinct clusters. This demonstrates effective partitioning of the dataset into broad cellular lineages. A small proportion of cells are labeled as unassigned (purple), appearing sparsely distributed.
- celltype_minor UMAP: This plot further resolves the major cell types into finer subsets, such as T cell CD8+ (dark blue), T cell CD4+ (light blue), Macrophage (yellow), Fibroblast (light orange), and Plasma cell (green), among others. These minor cell types largely maintain the overall structure established by the major cell types but show more granular segregation, confirming the utility of a multi-level annotation approach. The unassigned population remains small.
- celltype_subset UMAP: The most detailed level of annotation reveals highly specific cell populations, including Luminal epithelial cells, various macrophage subtypes (e.g., Macrophage (M1), Macrophage (M2A, M2B, M2C, M2D)), and diverse T cell subsets (e.g., T cell (Cytotoxic), T cell (Treg), T cell (Th17)). These subsets form coherent clusters, indicating high resolution in cell type identification and distinct gene expression profiles within broader cell lineages.
Ploidy Status
- ploidy_dec UMAP: Aneuploid cells (maroon) exhibit a striking localization, primarily found within specific clusters that largely correspond to the epithelial cell compartment (orange clusters in cell type plots). Diploid cells (yellow) are widely distributed across the majority of the UMAP, encompassing most non-epithelial cell types and some epithelial cells. A negligible number of cells are labeled Unclear (purple), suggesting high confidence in the ploidy inference for most cells.
Biological Interpretation
The UMAP visualizations reveal several key biological insights into the breast tissue scRNA-seq dataset:
- Disease-Associated Cellular Changes: The clear distinction between normal and primary_tumor cells on the UMAP highlights significant shifts in cellular composition, transcriptional states, or both, within the tumor microenvironment compared to healthy tissue. The existence of tumor-specific clusters strongly suggests the presence of unique cell populations or altered states critical to tumor biology.
- Robust Cell Type Identification: The consistent clustering of cells by major, minor, and subset annotations demonstrates the high quality and specificity of the cell type assignments. The hierarchical nature of the clustering, where finer subsets reside within broader categories, supports a biologically meaningful organization of cellular identities.
- Aneuploidy as a Tumor Hallmark: The pronounced co-localization of Aneuploid cells with the Epithelial cell clusters is a highly significant finding. Given that "Epithelial cell" is specified as the Tumor origin celltype, this observation strongly suggests that the malignant epithelial cells within the primary tumor exhibit aneuploidy. Aneuploidy, the presence of an abnormal number of chromosomes, is a well-established hallmark of cancer cells and is associated with tumor development and progression. This finding validates the genomic instability commonly observed in breast cancer and confirms the successful identification of the neoplastic compartment within the dataset PubMed: aneuploidy cancer review.
- Tumor Microenvironment Complexity: The detailed celltype_subset UMAP showcases the intricate cellular heterogeneity within the breast tissue, particularly within the tumor microenvironment. The identification of various immune cell subtypes (e.g., T cell (Treg), Macrophage (M1/M2 subtypes)), stromal cells (e.g., Fibroblast), and different epithelial populations provides a rich foundation for investigating cell-cell interactions and their roles in tumor progression or immune response.
Annotation Notes
The UMAP plots serve as an excellent quality control and validation step for the dataset.
- The strong concordance between unsupervised clustering and known biological annotations (cell types, conditions) indicates that the dimensionality reduction and clustering captured meaningful biological variation.
- The minimal sample-specific clustering suggests that any potential batch effects have been effectively mitigated or are not dominant enough to obscure biological signals.
- The small proportion of "unassigned" cells is typical for scRNA-seq analyses and likely represents either rare populations requiring deeper characterization, technical artifacts (e.g., doublets not fully removed), or cells with ambiguous transcriptional profiles. Further investigation of these "unassigned" cells might be warranted depending on the analytical goals.
- The clear separation of aneuploid from diploid cells and its strong correlation with the tumor epithelial compartment strengthens confidence in the ploidy inference and its biological relevance.
2. UMAP Visualization of Key Cell Type Markers and Minor Cell Type Annotations
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the expression levels of a panel of known cell type marker genes across the entire single-cell RNA-seq dataset, projected onto a UMAP embedding. Alongside these gene expression plots, a UMAP plot colored by celltype_minor annotations is provided as a reference. The purpose is to assess the consistency and quality of the predefined celltype_minor annotations against the expression patterns of canonical marker genes.
Visual Summary
The UMAP plots clearly delineate distinct clusters of cells. Each gene expression plot highlights specific regions of the UMAP with elevated expression (represented by warmer colors), corresponding to particular cell populations. The celltype_minor UMAP shows well-separated clusters for each annotated cell type, such as B cells, T cells (CD4+ and CD8+), Macrophages, Epithelial cells, Fibroblasts, Endothelial cells, etc.
Key observations from the visual comparison include:
- Lymphoid Cells: Genes like CD3D, CD4, CD8A, CD79A, MS4A1, and MZB1 show highly specific expression patterns, primarily confined to regions annotated as T cells, B cells, and Plasma cells.
- Myeloid Cells: CD14 and LYZ expression largely overlaps with the Macrophage and Dendritic cell clusters.
- Stromal Cells: FBLN1 and NOTCH3 are enriched in areas corresponding to Fibroblasts and Smooth muscle cells.
- Epithelial Cells: EPCAM and MUC1 exhibit strong, localized expression within the Epithelial cell clusters.
- Endothelial Cells: CD34 expression is distinctly localized to the Endothelial cell clusters.
Biological Interpretation
The expression patterns of the selected genes align remarkably well with their known biological roles as specific cell type markers, providing strong support for the accuracy of the celltype_minor annotations.
T Cell Markers:
- CD3D (part of the CD3 complex) is a pan T-cell marker, and its high expression is observed across both T cell CD4+ and T cell CD8+ clusters, as expected. GeneCards: CD3D
- CD4 expression is predominantly localized to the T cell CD4+ cluster, consistent with its role as a marker for helper T cells. GeneCards: CD4
- CD8A expression is similarly specific to the T cell CD8+ cluster, identifying cytotoxic T lymphocytes. GeneCards: CD8A
B Cell & Plasma Cell Markers:
- CD79A (part of the B-cell antigen receptor complex) and MS4A1 (CD20) are canonical B-cell markers, showing clear enrichment in the B cell cluster. GeneCards: CD79A, GeneCards: MS4A1
- MZB1 (Marginal zone B and B1 cell specific protein 1) is typically associated with plasma cells and B cell differentiation, and its expression is highly concentrated in the Plasma cell cluster. GeneCards: MZB1
Myeloid Cell Markers:
- CD14 and LYZ (Lysozyme) are widely recognized markers for monocytes, macrophages, and other myeloid cells. Their elevated expression in the Macrophage and Dendritic cell clusters confirms these myeloid populations. GeneCards: CD14, GeneCards: LYZ
Stromal Cell Markers:
- FBLN1 (Fibulin 1), an extracellular matrix protein, shows enrichment in the Fibroblast clusters, consistent with its role in stromal tissue organization. GeneCards: FBLN1
- NOTCH3, a receptor involved in cell development and differentiation, shows localized expression in regions that may correspond to Smooth muscle cell and subsets of Fibroblast or Endothelial cell populations, aligning with its diverse expression in various stromal and vascular contexts. GeneCards: NOTCH3
Epithelial Cell Markers:
- EPCAM (Epithelial Cell Adhesion Molecule) and MUC1 (Mucin 1) are robust markers for epithelial cells. Their expression is strongly confined to the Epithelial cell cluster, which is consistent with the tumor_origin_ind indicating epithelial cells as the tumor origin cell type in breast tissue. GeneCards: EPCAM, GeneCards: MUC1
Endothelial Cell Marker:
- CD34 is a well-known marker for endothelial cells and hematopoietic progenitor cells. Its expression is specifically enriched in the Endothelial cell cluster. GeneCards: CD34
Annotation Notes
The high concordance between the gene expression patterns and the celltype_minor annotations suggests that the cell type assignments are robust and accurate for the major cell populations represented in this breast tissue single-cell RNA-seq dataset. The clear separation of cell types on the UMAP and the specific localization of marker gene expression reinforce confidence in the underlying clustering and annotation process. This foundational check is critical for subsequent downstream analyses, such as differential gene expression or cell-cell interaction studies, ensuring that these analyses are performed on correctly identified cell populations.
3. Overall Celltype_subset Marker Expression Profile
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the expression of marker genes across different celltype_subset populations identified in the single-cell RNA-seq dataset from human breast tissue. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing a gene (dot size) for selected marker genes within each cell type. The primary goal is to assess the quality of the celltype_subset annotations by examining whether the expression patterns of these markers align with known cell type identities.
Visual Summary
The dot plot demonstrates a highly organized and distinct pattern of gene expression, with most marker genes showing strong specificity for particular celltype_subset groups.
- Distinct Clusters: Each celltype_subset generally exhibits a unique signature of highly expressed genes, often highlighted by the red boxes, indicating a successful identification of specific markers for each group.
- Marker Specificity and Expression: Genes within the red boxes typically display large, intensely colored dots, signifying both a high fraction of cells expressing the gene and high mean expression levels within that specific cell type. Conversely, these markers show minimal to no expression in other cell types, confirming their specificity.
- Cell Population Sizes: The bar plot on the right indicates the number of cells in each celltype_subset. Several populations, such as Luminal epithelial cells (24005 cells) and Macrophage (M2C) (23359 cells), are abundantly represented, providing robust data for marker assessment.
- Expected Overlaps: Some genes, like ACTA2, show expression in both Fibroblasts (consistent with myofibroblasts) and Smooth muscle cells, which is biologically expected given the shared contractile properties.
- Transcription Factor Markers: Notably, several key transcription factors (e.g., GATA3, RORC, FOXP3, XBP1, POU2F2, EBF1) are prominently displayed as markers, despite the find_cfg specifying surfaceome_only: True. These intracellular markers are highly valuable for defining cell identities.
Biological Interpretation
The observed marker gene expression patterns are largely consistent with established biological knowledge of cell types found in human breast tissue, affirming the quality of the celltype_subset annotations.
- B Cells (Breg, MZ, Memory): Marked by genes such as POU2F2, POU2F3, and EBF1, which are critical transcription factors for B cell development and function [1, 2]. CD86 is also observed, consistent with an antigen-presenting role.
- Endothelial Cells (Endothelial cell, Endothelial tip cell, Lymphatic Endothelial cell): Distinctly identified by ACKR1, ANGPT2, and ESM1 for general endothelial cells, and PROX1 and PDPN for lymphatic endothelial cells [3, 4]. These genes are involved in vascular formation, function, and lymphatic identity.
- Fibroblasts: Clearly characterized by extracellular matrix-related genes like DCN, LUM, COL1A1, COL3A1, FBLN1, FBLN2, as well as FAP and PDGFRA [5]. The presence of ACTA2 further indicates the presence of myofibroblast subsets.
- ILCs (ILC1, ILC2, ILC3, ILCreg): While showing some shared expression patterns, distinct transcription factors like GATA3 (ILC2), STAT4 (ILC1), and RORC (ILC3) help differentiate these innate lymphoid cell subsets [6].
- Macrophages (M1, M2A, M2B, M2C, M2D): Identified by the pan-macrophage marker CD68. CD86 expression aligns with pro-inflammatory M1 macrophages, while SPP1 (Osteopontin) is highly expressed in M2-like macrophages, implicated in tissue remodeling and immune modulation [7, 8].
- Epithelial Cells (Luminal epithelial cell, Mammary epithelial cell): Strongly characterized by keratin genes (KRT8, KRT18, KRT19), CDH1 (E-cadherin), MUC1, and PIP, which are canonical markers of epithelial cells and mammary gland lineage [9, 10].
- Mast Cells: Robustly identified by mast cell-specific proteases TPSAB1 and TPSB2, along with KIT (CD117), a receptor critical for mast cell development, and the transcription factor GATA2 [11, 12].
- Plasma Cells: Characterized by the strong expression of XBP1, a key transcription factor essential for plasma cell differentiation and antibody secretion [13].
- Smooth Muscle Cells: Distinctly marked by ACTA2 (alpha-smooth muscle actin), CALD1, TPM2, and TAGLN, which are involved in muscle contraction and smooth muscle cell identity [14].
- T Cells (Cytotoxic, Naive, Tfh, Th1, Th17, Th2, Th22, Treg): These subsets are well-resolved by classical markers. For example, CD8A/CD8B and granzymes (GZMK, GZMB) for cytotoxic T cells; SELL for naive T cells; PDCD1 for T follicular helper (Tfh) cells; STAT1 and IFNGR1 for Th1 cells; RORA and RORC for Th17 cells; GATA3 and STAT5B for Th2 cells; and FOXP3, CTLA4, and TNFRSF4 (OX40) for regulatory T cells (Tregs) [15, 16, 17, 18].
Annotation Notes
The comprehensive and specific marker expression patterns observed across the celltype_subset populations strongly validate the current cell type annotations within the AnnData object. The ability to identify both surface proteins and key intracellular transcription factors further enhances confidence in the fine-grained resolution of these cell identities. This robust annotation forms a solid foundation for subsequent in-depth analyses, such as differential gene expression or cell-cell interaction studies, ensuring that these analyses are performed on accurately defined cell populations.
References
- POU2F2 (OCT2): GeneCards (GeneCards)
- EBF1: GeneCards (GeneCards)
- ACKR1 (DARC): GeneCards (GeneCards)
- PROX1: GeneCards (GeneCards)
- FAP: GeneCards (GeneCards)
- ILC transcription factors: PubMed Search: "ILC differentiation transcription factors" (PubMed Search)
- CD68: GeneCards (GeneCards)
- SPP1 (Osteopontin): GeneCards (GeneCards)
- Keratins (KRT8, KRT18): GeneCards (GeneCards), (GeneCards)
- PIP: GeneCards (GeneCards)
- TPSAB1 (Tryptase): GeneCards (GeneCards)
- KIT: GeneCards (GeneCards)
- XBP1: GeneCards (GeneCards)
- ACTA2: GeneCards (GeneCards)
- CD8A: GeneCards (GeneCards)
- FOXP3: GeneCards (GeneCards)
- CTLA4: GeneCards (GeneCards)
- T cell subsets: PubMed Search: "T cell subset markers" (PubMed Search)
4. Copy Number Variation Analysis in Tumor-Origin and Unassigned Cells Grouped by Sample
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates copy number variations (CNVs) in Epithelial cells (identified as the tumor-origin cell type) and 'unassigned' cells, grouped by individual sample. The goal is to visualize CNV patterns across the genome for each sample and provide a summary of significantly amplified or deleted regions. This helps in understanding the genomic instability characteristic of cancer cells and validating the ploidy status of the samples.
Visual Summary
The visualization consists of two main parts: a CNV heatmap and a summary of significant CNV regions.
CNV Heatmap
- Genomic Instability Profile: The main heatmap displays log2(Copy Number Ratio) values across genomic spots for each sample. Red/yellow colors indicate regions of copy number gain (amplification), while blue colors represent copy number loss (deletion). White/light yellow indicates a neutral copy number state.
- Ploidy-based Segregation: Samples are clearly stratified into two groups: "Diploid Patient" samples (top block) and "Patient" samples (bottom block).
- "Diploid Patient" Group: This group consistently shows minimal to no significant CNVs, largely appearing as a uniform white-to-light blue/red background, indicating a stable, diploid genome. This aligns with their 'Diploid' designation and suggests a non-malignant or benign genomic profile for the analyzed cell types within these samples.
- "Patient" Group: In stark contrast, the "Patient" samples exhibit extensive and heterogeneous CNV patterns. Multiple regions of significant amplification (red/yellow) and deletion (blue) are evident across various chromosomes. This high degree of genomic instability is a hallmark of aneuploidy and malignancy, consistent with their implied 'Aneuploid' status and likely tumor origin.
- Recurrent CNV Regions: Within the "Patient" group, several chromosomal arms show recurrent alterations:
- Amplifications: Frequent gains are observed on chromosome arms such as 1q, 8q, 11q, 17q, and 20q. For instance, Patient_9_3B3E9L_RNA shows prominent amplifications on 1q, 8q, and 17q, while Patient_14_43E7BL_RNA has strong amplifications on 1q, 8q, 11q, 17q, and 20q.
- Deletions: Recurrent losses are less uniform but can be seen, for example, on regions of chromosome 1, 6, and 16.
- Inter-sample Heterogeneity: While common patterns exist, there is considerable variability in the specific CNV profiles among different "Patient" samples, highlighting the genomic heterogeneity often observed in tumors.
Summary of Significantly Amplified Copy Number Regions
- Frequency of CNVs: The summary plots (left heatmap and right bar chart) highlight the most frequently altered cytogenetic bands across the "Patient" samples. The left heatmap shows the frequency of significant CNVs per cytogenetic band for each of the "Patient" samples.
- Top Recurrent Amplifications: The bar chart on the right quantifies the frequency of these alterations. The most frequently amplified regions (frequencies > 0.5) include:
- 1q41:1q44 (Frequency: 0.82) – This region is very frequently amplified, observed in the majority of aneuploid samples.
1q21.3:1q23.2 (Frequency: 0.64)
1q23.3:1q24.1 (Frequency: 0.45)
- 1q32.1:1q32.2 (NFASC) (Frequency: 0.27) – Contains the *NFASC* gene.
- 8q22.1:8q23.1 (EIF3E) (Frequency: 0.36) – Contains the *EIF3E* gene.
11q13.4:11q21 (Frequency: 0.27)
- 20q13.13:20q13.2 (Frequency: 0.27) – This region is often amplified in breast cancer.
- Specific Genes: The summary highlights genes within some of these amplified regions, such as *NFASC* (Neurofascin) on 1q32.1:1q32.2 and *EIF3E* (Eukaryotic Translation Initiation Factor 3 Subunit E) on 8q22.1:8q23.1, suggesting their potential involvement in disease progression when amplified.
Biological Interpretation
- Confirmation of Tumor Status: The stark contrast in CNV burden between "Diploid Patient" and "Patient" samples strongly supports the accurate classification of these samples based on their ploidy status. The "Patient" samples, exhibiting widespread CNVs in Epithelial cells (the designated tumor-origin cell type) and 'unassigned' cells, are highly indicative of malignant tumor tissue. The 'unassigned' cells showing similar CNV patterns might represent tumor cells that could not be assigned to a specific epithelial subtype or are part of the tumor microenvironment with genomic alterations.
- Genomic Landscape of Breast Cancer: The identified recurrent CNVs, such as amplifications on 1q, 8q, 11q, and 20q, are well-established genomic alterations in breast cancer PMID: 29038234. These regions often harbor oncogenes whose increased copy number contributes to tumor initiation and progression.
- 1q Amplification: Gains in 1q are frequent in various cancers, including breast cancer, and can involve genes associated with cell proliferation and survival.
- 8q Amplification: Amplification of 8q is a common event in breast cancer and often includes the *MYC* oncogene, which drives cell growth and division. The identified *EIF3E* gene within 8q22.1:8q23.1 is involved in protein synthesis and has been implicated in cancer development and progression.
- 11q Amplification: The 11q13 region, often amplified, is known to contain genes like *CCND1* (cyclin D1), which plays a critical role in cell cycle regulation and is a key driver in a subset of breast cancers.
- 20q Amplification: Gains on 20q are also recurrent in breast cancer and are associated with tumor aggressiveness.
- Potential Driver Genes: The specific genes highlighted (*NFASC*, *EIF3E*) within recurrently amplified regions warrant further investigation. *NFASC* (Neurofascin) is involved in cell adhesion and neural development, but its role in breast cancer, particularly upon amplification, could suggest altered cell-cell or cell-extracellular matrix interactions that contribute to tumor invasion and metastasis. *EIF3E* (Eukaryotic Translation Initiation Factor 3 Subunit E) plays a role in initiating protein synthesis, and its overexpression due to amplification could lead to increased translation of oncogenic proteins, promoting cell growth and survival.
Clinical or Translational Implications
- Prognostic and Predictive Biomarkers: Recurrent CNVs, especially those affecting known oncogenes, can serve as prognostic indicators for disease progression or as predictive biomarkers for response to targeted therapies. For example, amplification of *HER2* (not explicitly shown here but a classic example of a CNV-driven oncogene on 17q) guides anti-HER2 therapies in breast cancer. The recurrent amplifications identified here could be explored for similar clinical utility.
- Target Identification: The identified genes within amplified regions, such as *NFASC* and *EIF3E*, represent potential candidates for further research into their functional roles in breast cancer and their suitability as therapeutic targets. Understanding how their amplification contributes to tumor biology could pave the way for novel therapeutic strategies.
- Annotation Validation: This analysis strongly validates the ploidy_dec annotation, demonstrating clear genomic differences between "Diploid Patient" and "Patient" samples. This helps ensure that downstream analyses distinguishing between normal and tumor samples are based on robust genomic evidence, which is crucial for accurate biological and clinical interpretations.
5. CNV-based UMAP Visualization of Single-Cell RNA-seq Data
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a Uniform Manifold Approximation and Projection (UMAP) visualization where the embedding (X_cnv_umap1, X_cnv_umap2) is specifically computed using copy number variation (CNV) estimates from single-cell RNA-seq data. The resulting UMAP plots illustrate how cells group based on their CNV profiles, overlaid with annotations for major cell types, minor cell types, ploidy status (Aneuploid/Diploid), biological condition (normal/primary_tumor), and individual sample origin. This allows for an assessment of the relationship between genomic alterations (CNVs/ploidy) and cellular identity, disease state, and inter-sample variability.
Visual Summary
The five UMAP plots collectively reveal distinct patterns driven by cellular CNV profiles:
- celltype_major: The UMAP displays a primary large cluster and several smaller, more distinct clusters. Epithelial cells (Epi) form a large, diffuse cluster that appears central and extensively spread across the main UMAP space, often overlapping with other cell types but also forming distinct regions. T cells (T cell) and Myeloid cells (Myeloid cell) occupy relatively distinct regions, particularly in the lower-right and upper-left parts of the main cluster, respectively. B cells (B cell) and Endothelial cells (Endo) form smaller, more defined clusters, with B cells typically appearing as a tight cluster at the top-left periphery and Endothelial cells showing scattered presence. Stromal cells (Stromal cell) are broadly distributed but also show some clustering. Unassigned cells form small, isolated groups.
- celltype_minor: This plot refines the observations from the major cell type plot. For instance, Macrophages (Mac) from the Myeloid cell major group show specific localization within the myeloid cluster. T cell CD8+ and T cell CD4+ also show some separation within the T cell regions. Epithelial cells remain broadly distributed, indicating potential heterogeneity within this tumor-originating population, as specified in the data context.
- ploidy_dec: This UMAP plot strongly segregates cells based on ploidy status. A significant proportion of cells are labeled as Aneuploid (dark red), which predominantly co-localize with the larger, more diffuse clusters of Epithelial cells. In contrast, Diploid cells (light yellow) form distinct, more compact clusters that largely correspond to immune cells (T cells, B cells) and stromal cells, as well as some epithelial cells. A smaller number of Unclear cells are scattered. This suggests a strong correlation between CNV-derived UMAP structure and ploidy.
- condition: This plot shows a clear separation between normal (dark red) and primary_tumor (dark blue) cells. The primary_tumor cells broadly overlap with the Aneuploid population and the main Epithelial cell clusters. Normal cells are largely confined to the clusters identified as Diploid, corresponding mostly to immune and stromal cell populations, and some non-malignant epithelial cells. However, there is some mixing, particularly where normal cells might represent normal epithelial cells or stromal/immune cells infiltrating the tumor microenvironment.
- sample: This plot indicates that cells from different samples (patients) are largely intermixed within the major clusters, suggesting that shared CNV patterns (and thus cell types or conditions) drive the overall UMAP structure more than individual patient-specific batch effects for the CNV profiles. However, some smaller, peripheral clusters appear to be dominated by cells from one or a few specific samples, indicating patient-specific CNV events or highly unique cell populations. For example, the upper-left B cell cluster shows mixed sample origins, but some specific small clusters might be patient-specific.
Biological Interpretation
The UMAP visualization, based on CNV estimates, provides critical insights into the genomic landscape of the breast tissue samples:
- CNV-driven Cell Type and Condition Segregation: The most striking observation is the clear separation of Aneuploid cells, which predominantly belong to the primary_tumor condition and are identified as Epithelial cell (the 'Tumor origin celltype'). This strongly suggests that CNVs are a major driver of cellular heterogeneity in this dataset, effectively separating malignant epithelial cells from non-malignant stromal and immune cells. The clustering of normal cells and non-epithelial cell types (T cells, B cells, Myeloid, Stromal) into Diploid regions is consistent with their expected genomic stability in comparison to tumor cells.
- Tumor Malignancy and Aneuploidy: The extensive presence of Aneuploid cells specifically within the primary_tumor condition, co-localizing with Epithelial cell populations, is a hallmark of cancer. Aneuploidy, the presence of an abnormal number of chromosomes, is a well-established driver of tumorigenesis and progression. The CNV-based UMAP effectively captures this fundamental genomic alteration. PubMed search: "cancer aneuploidy role tumorigenesis"
- Heterogeneity within Tumor Epithelial Cells: The Epithelial cell cluster, especially within the primary_tumor context, appears diffuse and broadly distributed across the CNV UMAP space. This suggests considerable intra-tumoral heterogeneity in CNV profiles among malignant epithelial cells, which could reflect different subclones or stages of tumor evolution.
- Tumor Microenvironment Cells: Immune cells (T cells, B cells, Myeloid cells) and Stromal cells, whether in normal or tumor conditions, primarily reside in the Diploid regions. This indicates that these non-malignant components of the tissue and tumor microenvironment largely maintain a normal chromosome complement, even when associated with a tumor. Their distinct clustering on the CNV UMAP suggests that even without gross aneuploidy, there might be subtle, characteristic CNV patterns or gene expression profiles (which correlate with CNV estimates derived from RNA-seq) that distinguish them.
- Patient-Specific CNV Signatures: While overall cell types and conditions drive the major UMAP structure, the sample plot hints at some degree of patient-specific CNV patterns, particularly in smaller, more isolated clusters. This underscores the genetic individuality of tumors and could indicate unique clonal expansions or specific CNV events in certain patients.
Annotation Notes
- The quality of cell type annotation is supported by the clear segregation of Diploid cells with known non-malignant cell types (e.g., T cells, B cells) and Aneuploid cells with the designated Tumor origin celltype (Epithelial cell) within the primary_tumor condition.
- The embedding structure strongly reflects underlying CNV profiles, validating the use of X_cnv for dimensionality reduction in this context. The separation of normal and tumor conditions is a key indicator of effective CNV-based discrimination.
- The sample-level distribution suggests that the primary biological signals (cell type and condition-specific CNVs) are robust across different patients, though individual patient variations are also observable, as expected in heterogeneous disease cohorts.
6. Minor Cell Type Population Analysis in Breast Tissue: Normal vs. Primary Tumor
[Analysis Visualization Results]...
Analysis Overview
This analysis provides a comprehensive view of the cellular composition, specifically focusing on minor cell type proportions, across different samples of normal breast tissue and primary breast tumors. The stacked bar plots normalize the cell counts within each sample to 100%, allowing for direct comparison of relative cell type abundances between conditions and across individual patients. This is crucial for understanding the overall cellular ecosystem in health and disease.
Visual Summary
The stacked bar plots display the relative proportions of various minor cell types for each sample, categorized by 'normal' and 'primary_tumor' conditions.
- Normal Breast Tissue (Left Panel): The normal samples exhibit a relatively consistent cellular composition. Epithelial cells (orange) and Fibroblasts (light orange) constitute the largest proportions, reflecting the glandular and stromal components of healthy breast tissue. Endothelial cells (red-orange) are also consistently present, along with smaller, but identifiable, populations of T cells (CD4+ and CD8+) (teal/light teal), indicative of immune surveillance. Other immune cell types (e.g., Macrophages, B cells) are present in very low frequencies. The proportion of 'unassigned' cells is minimal across all normal samples.
- Primary Tumor Tissue (Right Panel): Primary tumor samples show greater heterogeneity in cell type proportions compared to normal tissues.
- Epithelial cells (orange) generally remain a dominant cell type, consistent with their role as the tumor origin cell type.
- Fibroblasts (light orange) are also highly abundant, indicating a substantial stromal component within the tumor microenvironment.
- Macrophages (light yellow) show a noticeable increase in many tumor samples compared to normal tissue, suggesting increased immune cell infiltration.
- Endothelial cells (red-orange) are consistently present, likely supporting tumor angiogenesis.
- T cells (CD4+ and CD8+) (teal/light teal) are present but highly variable across tumor samples, with some samples showing higher T cell infiltration than others.
- A significant observation is the presence of a substantial proportion of 'unassigned' cells (dark blue) in several primary tumor samples (e.g., Patient_5, Patient_10, Patient_11, Patient_7), sometimes comprising up to ~50% of the total cells in a sample. This indicates either novel cell states not captured by current annotations or challenges in classifying highly aberrant or dedifferentiated cells within tumors.
- Other immune cell types like B cells and Plasma cells are present in low, variable proportions.
Biological Interpretation
The observed shifts in minor cell type populations between normal breast tissue and primary tumors highlight significant alterations in the cellular landscape during breast cancer progression.
- Tumor-associated Stromal and Immune Remodeling: The consistent dominance of Epithelial cells and Fibroblasts in tumors, along with an increase in Macrophages, reflects the well-established features of the tumor microenvironment (TME). Tumor-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) are critical components of the TME, promoting tumor growth, invasion, angiogenesis, and immunosuppression [1]. The data shows an upregulation of macrophage presence in tumor samples, suggesting an active role for these immune cells in the disease context.
- Heterogeneity of Anti-tumor Immune Response: The variable presence of T cells (CD4+ and CD8+) in primary tumor samples points to inter-patient heterogeneity in immune infiltration. Some tumors appear "hot" (more infiltrated by T cells), while others are "cold" (less infiltrated). This heterogeneity is a known factor influencing patient response to immunotherapy in breast cancer [2].
- Significance of 'Unassigned' Cells: The high proportion of 'unassigned' cells in certain primary tumor samples is noteworthy. These cells could represent:
- Tumor Cells with Aberrant Phenotypes: Highly malignant or dedifferentiated tumor cells that deviate significantly from canonical epithelial cell markers.
- Novel Cell States: Unique cell states induced by the tumor microenvironment that do not fit existing classification schemes (e.g., transitional cell states, highly stressed cells).
- Technical Challenges: Cells with low RNA capture efficiency or complex transcriptomic profiles that are difficult to confidently annotate. Further investigation into these 'unassigned' populations using alternative annotation methods or marker gene analysis would be crucial for a complete understanding of tumor composition.
Clinical or Translational Implications
Understanding the precise cellular composition of breast tumors has several clinical and translational implications:
- Biomarker Discovery and Prognosis: Variations in the proportions of specific cell types, such as the increase in TAMs or the degree of T cell infiltration, can serve as prognostic biomarkers for breast cancer patients [3, 4]. For instance, high TAM density is often associated with poor prognosis, while certain T cell subsets can be linked to better outcomes.
- Therapeutic Targeting: The enrichment of specific cell types within the tumor microenvironment, like fibroblasts or macrophages, suggests potential targets for novel therapies aimed at modulating the TME and enhancing anti-tumor responses. For example, strategies to deplete TAMs or reprogram their phenotype are under investigation [1].
- Immunotherapy Response Prediction: The observed variability in T cell infiltration among primary tumors underscores the need for patient stratification in immunotherapy. Patients with higher T cell infiltration might be more responsive to immune checkpoint inhibitors, while those with "cold" tumors may require combination therapies to increase immune cell recruitment [2].
- Improving Cell Annotation: The substantial 'unassigned' cell population in tumors highlights a potential gap in current single-cell annotation efforts for complex disease states. Resolving the identity of these cells could uncover novel cellular players in breast cancer biology, potentially leading to the discovery of new therapeutic targets or resistance mechanisms.
---
References:
[1] Macrophage Biology and Breast Cancer: NCBI (PubMed Central for a review on TAMs)
[2] Tumor-infiltrating lymphocytes in breast cancer: NCBI (PubMed Central for a review on TILs in breast cancer)
[3] Prognostic value of tumor-infiltrating lymphocytes in breast cancer: PubMed Search (PubMed search for "prognostic value tumor-infiltrating lymphocytes breast cancer")
[4] Tumor-associated macrophages in breast cancer prognosis: PubMed Search (PubMed search for "tumor-associated macrophages breast cancer prognosis")
7. T Cell and Innate Lymphoid Cell Subpopulation Analysis in Breast Cancer
[Analysis Visualization Results]...
Analysis Overview
This analysis utilizes single-cell RNA sequencing data to characterize the cellular composition of the 'T cell' major population, further broken down into various T cell subsets and innate lymphoid cells (ILCs), across normal breast tissue and primary breast tumor samples. The plot_celltype_population tool was used to visualize the relative proportions of these immune cell subsets within each individual sample, categorized by 'condition' (normal vs. primary_tumor). This provides insights into the immune landscape shifts associated with breast tumorigenesis.
Visual Summary
The stacked bar plot effectively illustrates the relative proportions of T cell and ILC subsets for each sample, grouped by condition.
- Overall Composition: The T cell_major compartment, as defined in this analysis (including ILCs and NK cells), is complex and diverse in both normal and tumor tissues. Lymphoid Tissue Inducer (LTI) cells and Natural Killer (NK) cells frequently represent substantial proportions of this compartment in many samples.
Normal vs. Primary Tumor Differences:
- Increased Cytotoxic T cells in Tumors: Several primary tumor samples (e.g., Patient_14_43E7CL_RNA, Patient_5_35A4AL_RNA, Patient_15_45CB0L_RNA, Patient_13_3D388L_RNA) exhibit a noticeable increase in the proportion of T cell (Cytotoxic) cells (light yellow segment) compared to normal samples, where they are generally less abundant. This suggests an active cytotoxic immune response in a subset of tumors.
- Variable T regulatory cells (Tregs): T cell (Treg) populations (teal segment) are present in small proportions across both conditions. While generally low, some tumor samples show a slightly higher relative presence compared to normal tissue.
- Heterogeneity in Tumor Microenvironment: The primary tumor samples display greater heterogeneity in their immune cell subset composition compared to the relatively consistent profiles observed in normal samples. This variability highlights patient-specific immune responses within the tumor microenvironment.
- "Unassigned" Cells: The proportion of "unassigned" cells (dark blue segment at the top of the bars) appears to be generally higher and more variable in primary tumor samples compared to normal samples. This could indicate novel or uncharacterized immune cell states emerging in the tumor context, or limitations in annotation for tumor-specific immune phenotypes.
- ILC Distribution: Innate lymphoid cell (ILC) subsets (ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg) are consistently present in both conditions. While their specific relative abundances vary across samples, no clear, consistent shifts across *all* tumor samples compared to normal are immediately evident from this visualization for individual ILC types.
Biological Interpretation
The observed shifts in T cell and ILC subset populations between normal breast tissue and primary tumors provide key biological insights into the immune microenvironment of breast cancer.
- Anti-Tumor Immunity: The increased proportion of T cell (Cytotoxic) cells in a subset of primary tumor samples suggests an attempt by the immune system to mount an anti-tumor response. Cytotoxic T lymphocytes (CTLs) are crucial for directly killing cancer cells. Their presence is often correlated with better prognosis and responsiveness to immunotherapy in various cancers, including breast cancer. PubMed search: Cytotoxic T cells breast cancer prognosis
- Immune Evasion and Suppression: The potential, albeit subtle, increase in T cell (Treg) populations in some tumor samples is concerning. Tregs are immunosuppressive cells that can inhibit the activity of anti-tumor effector cells, facilitating tumor growth and immune evasion. GeneCards: FOXP3 (FOXP3 is a canonical marker for Tregs). The balance between cytotoxic T cells and Tregs is critical in determining the efficacy of anti-tumor immunity.
- Role of Helper T Cells and ILCs: The diverse presence of various T helper subsets (Th1, Th2, Th17, etc.) and ILCs (ILC1, ILC2, ILC3) underscores the complexity of adaptive and innate immune responses in breast tissue.
- Th1 cells and ILC1s are generally associated with pro-inflammatory and anti-tumor responses.
- Th2 cells and ILC2s can sometimes promote tumor growth or contribute to an immunosuppressive environment.
- Th17 cells and ILC3s have context-dependent roles, being either pro- or anti-tumorigenic.
- The prominent presence of LTI cells (Lymphoid Tissue Inducer cells) and ILCreg suggests active roles of innate lymphoid cells in shaping the immune architecture, potentially contributing to lymphoid neogenesis or immune regulation within the breast tissue. PubMed search: Innate lymphoid cells breast cancer
- Unassigned Cell Populations: The higher "unassigned" fraction in tumors might represent novel or transcriptionally altered immune cell states induced by the tumor microenvironment that do not fit into existing common immune cell annotations. Further investigation into these cells could uncover new immune cell phenotypes relevant to breast cancer.
Clinical or Translational Implications
- Immunotherapy Response Prediction: The varied immune cell landscape, particularly the presence and proportion of cytotoxic T cells, could serve as a biomarker for predicting patient response to immunotherapies. Patients with a higher cytotoxic T cell infiltration might be more responsive to immune checkpoint inhibitors.
- Therapeutic Target Identification: An increased Treg presence in tumors highlights a potential therapeutic strategy: targeting Tregs to overcome immune suppression and enhance anti-tumor responses. Similarly, understanding the roles of specific ILC subsets could open avenues for novel immune-modulating therapies.
- Prognostic Value: The specific ratios or abundances of T cell and ILC subsets might have prognostic value, informing disease progression and patient outcomes in breast cancer.
- Understanding Tumor Heterogeneity: The substantial inter-patient heterogeneity in immune cell composition within primary tumors emphasizes the need for personalized approaches in breast cancer treatment, where immune profiling of individual tumors could guide therapeutic decisions.
8. Macrophage Subset Population Analysis in Breast Tissue: Normal vs. Primary Tumor
[Analysis Visualization Results]...
Analysis Overview
This analysis utilizes single-cell RNA sequencing data to visualize the proportional distribution of different macrophage subsets (M1, M2A, M2B, M2C, M2D) within individual samples, comparing normal breast tissue to primary breast tumor samples. The plot_celltype_population tool was used to specifically focus on the 'Macrophage' celltype_minor and further stratify them by their 'subset' classifications.
Visual Summary
The stacked bar plots display the relative proportions of five distinct macrophage subsets (M1, M2A, M2B, M2C, M2D) across individual samples grouped by condition ('normal' and 'primary_tumor').
- Normal Samples: In normal breast tissue, Macrophage (M2B) appears to be the most dominant subset, consistently forming a large proportion of the total macrophages across the four normal samples. Macrophage (M1) is present but generally at lower proportions compared to M2B. Macrophage (M2C) and (M2D) are also present, with M2A being a minor component.
- Primary Tumor Samples: The macrophage landscape in primary tumor samples shows a notable shift and increased heterogeneity compared to normal tissue.
- Increased M1 Proportion: Macrophage (M1) (dark red) appears to contribute a larger proportion of the total macrophages in many primary tumor samples compared to normal samples. In several tumor samples, M1 is either the dominant or a very substantial subset.
- Persistent M2 Subsets: While M1 seems to increase, Macrophage (M2B) (light yellow) and Macrophage (M2C) (light green) remain prominent and represent significant fractions in primary tumor samples. This indicates that a complex mix of M1 and M2 phenotypes co-exists in the tumor microenvironment.
- Variability Across Tumor Samples: There is considerable inter-patient variability within the primary tumor group. Some tumor samples show a higher M1 proportion (e.g., Patient_15, Patient_8), while others maintain a larger fraction of M2B or M2C (e.g., Patient_14_43E7CL, Patient_9_3B3E9L). Macrophage (M2A) and (M2D) generally remain minor components, similar to normal tissue, but their exact proportions also vary.
Biological Interpretation
Macrophages are critical components of the tumor microenvironment (TME) and are highly plastic, polarizing into various phenotypes, broadly categorized as M1 (pro-inflammatory, anti-tumorigenic) and M2 (anti-inflammatory, pro-tumorigenic). The observed shifts in macrophage subsets provide insights into the immune landscape of breast cancer.
- Normal Tissue Homeostasis: The dominance of M2B macrophages in normal breast tissue might reflect their role in tissue homeostasis, immune regulation, or resolution of inflammation in a healthy context. M2 macrophages are known to be involved in tissue repair and maintaining immune tolerance [1].
- Tumor Microenvironment Remodeling: In primary tumors, the relative increase in M1 macrophages suggests an ongoing pro-inflammatory immune response attempting to combat the tumor. M1 macrophages are characterized by their ability to produce pro-inflammatory cytokines, present antigens, and directly kill tumor cells or pathogens [2].
- Co-existence of M1 and M2 Phenotypes: Despite the potential increase in M1, the sustained high proportions of M2B and M2C macrophages in the tumor indicate a complex and often contradictory immune environment. M2 macrophages, particularly M2C and M2D (also known as tumor-associated macrophages or TAMs), are often associated with immune suppression, promoting tumor growth, angiogenesis, and metastasis [3]. The persistent presence of M2B and M2C subsets suggests that while there might be an active anti-tumor M1 response, immunosuppressive and pro-tumorigenic signals are also robustly present, potentially dampening the overall anti-tumor efficacy.
- Heterogeneity in Tumor Immune Response: The significant sample-to-sample variability in macrophage subset composition within the primary tumor group underscores the individual differences in immune responses to cancer. This heterogeneity highlights that breast tumors might employ diverse strategies to shape their local immune microenvironment.
Clinical or Translational Implications
Understanding the balance and distribution of macrophage subsets has significant implications for breast cancer diagnosis, prognosis, and therapeutic strategies.
- Prognostic Value: The specific ratios of M1 to M2 macrophages have been associated with patient outcomes in various cancers, including breast cancer. A higher M1/M2 ratio might correlate with a better prognosis, while M2 dominance could indicate a worse prognosis and resistance to therapy [4].
- Therapeutic Targeting: The dual presence of both M1 and M2 phenotypes suggests potential therapeutic avenues:
- Repolarization Strategies: Efforts to repolarize pro-tumor M2 macrophages towards an anti-tumor M1 phenotype could enhance anti-cancer immunity [5].
- Inhibition of M2 Functions: Targeting specific M2 pathways or their recruitment could disrupt tumor-promoting immune suppression.
- M1 Augmentation: Strategies to boost M1 macrophage activity could improve the efficacy of existing immunotherapies.
- Personalized Medicine: The observed inter-patient heterogeneity emphasizes the need for personalized approaches in oncology. Characterizing the individual patient's macrophage landscape could guide treatment selection and predict response to immunotherapies, particularly those targeting the myeloid compartment.
References:
- M2 Macrophage Roles: PubMed search for "M2 macrophages tissue repair immune regulation" https://pubmed.ncbi.nlm.nih.gov/?term=M2+macrophages+tissue+repair+immune+regulation
- M1 Macrophage Functions: PubMed search for "M1 macrophages anti-tumor immunity" https://pubmed.ncbi.nlm.nih.gov/?term=M1+macrophages+anti-tumor+immunity
- M2 and TAMs in Cancer: PubMed search for "M2 macrophages tumor associated macrophages cancer" https://pubmed.ncbi.nlm.nih.gov/?term=M2+macrophages+tumor+associated+macrophages+cancer
- M1/M2 Ratio Prognosis: PubMed search for "M1 M2 ratio prognosis cancer" https://pubmed.ncbi.nlm.nih.gov/?term=M1+M2+ratio+prognosis+cancer
- Macrophage Repolarization Therapy: PubMed search for "macrophage repolarization cancer therapy" https://pubmed.ncbi.nlm.nih.gov/?term=macrophage+repolarization+cancer+therapy
9. Analysis of T Cell Subset Proportions in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the proportions of specific T cell subset populations (T follicular helper cells (Tfh), Regulatory T cells (Treg), and Lymphoid Tissue Inducer cells (LTI)) within single-cell RNA-seq data from human breast tissue. The aim is to identify statistically significant differences in these cell type proportions between 'primary_tumor' and 'normal' conditions, providing insights into the immune microenvironment shifts associated with breast cancer.
Visual Summary
The boxplots illustrate the celltype proportion (as a percentage of total cells) for three T cell subsets across primary tumor and normal breast tissue samples. Black dots represent individual sample measurements, while the boxes indicate the interquartile range (IQR), with the line inside representing the median. Statistical significance between conditions is indicated by p-values.
- Tfh (T follicular helper cells): The proportion of Tfh cells is significantly higher in primary_tumor samples compared to normal tissue (p ≤ 0.05). The median Tfh proportion in tumors appears to be around 5-6%, while in normal tissue, it is approximately 1-2%.
- Treg (Regulatory T cells): Similar to Tfh cells, Treg cell proportions are significantly elevated in primary_tumor samples compared to normal tissue (p ≤ 0.05). The median Treg proportion in tumors is around 4-5%, whereas in normal tissue, it is approximately 1-2%.
- LTI (Lymphoid Tissue Inducer cells): In contrast to Tfh and Treg cells, the proportion of LTI cells is significantly lower in primary_tumor samples compared to normal tissue (p ≤ 0.01). The median LTI proportion in normal tissue is considerably higher, around 45-47%, while in primary tumors, it is approximately 30-32%.
Biological Interpretation
The observed shifts in T cell subset proportions between primary breast tumors and normal tissue highlight significant alterations in the immune landscape during oncogenesis.
- Elevated Tfh cells in Primary Tumors: Tfh cells are crucial orchestrators of humoral immunity, primarily by assisting B cell differentiation and antibody production within germinal centers. While classically associated with protective immune responses, their role in cancer is complex. An increase in Tfh cells in the tumor microenvironment (TME) could indicate an attempt at an anti-tumor humoral response or, conversely, may contribute to pro-tumorigenic B cell responses or the development of tertiary lymphoid structures (TLS) that can either promote or inhibit tumor growth depending on their composition and activation state.
- Increased Treg cells in Primary Tumors: The significant enrichment of Regulatory T cells (Tregs) in primary breast tumors is a well-documented phenomenon across many cancer types. Tregs are powerful immunosuppressive cells that suppress effector T cells (e.g., CD8+ cytotoxic T lymphocytes) and other immune cells, thereby creating an immune-tolerant environment that facilitates tumor growth and metastasis. Their increased presence is often correlated with poor prognosis and resistance to immunotherapy. [PubMed Search: "Treg breast cancer prognosis"]
- Reduced LTI cells in Primary Tumors: Lymphoid Tissue Inducer (LTI) cells are vital for the formation and organization of secondary lymphoid organs and tertiary lymphoid structures (TLS) in non-lymphoid tissues. TLS within the tumor microenvironment are increasingly recognized as critical sites for local anti-tumor immune responses, often correlating with better patient outcomes. The observed significant decrease of LTI cells in primary tumors suggests a potential impairment in the ability to form or maintain organized lymphoid structures within the cancerous tissue. This reduction could contribute to a less organized and potentially less effective anti-tumor immune response, hindering the local priming and expansion of effector immune cells.
Clinical or Translational Implications
The differential proportions of T cell subsets between primary tumors and normal breast tissue carry important clinical and translational implications:
- Biomarkers and Prognosis: The relative abundance of Tfh, Treg, and LTI cells could serve as prognostic biomarkers in breast cancer. Specifically, high Treg infiltration is generally associated with a worse prognosis, while the significance of Tfh and LTI changes requires further investigation in the context of specific breast cancer subtypes and treatment responses.
- Immunotherapy Response: The immunosuppressive TME, partly characterized by increased Tregs and potentially diminished LTI-mediated immune organization, can impact the efficacy of immunotherapies. Strategies to deplete or inhibit Tregs, or to promote the formation and maturation of functional TLS (which might be affected by LTI cell numbers), could enhance anti-tumor immunity and improve patient outcomes.
- Targeting the Tumor Microenvironment: Understanding the precise roles of Tfh and LTI cells in breast cancer pathogenesis could open new avenues for therapeutic intervention, alongside established strategies targeting Treg-mediated immunosuppression. Modulating the immune contexture by influencing these specific T cell subsets might represent a valuable approach for combination therapies.
10. Ploidy Population Analysis of Epithelial and Unassigned Cells in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) within the population of 'Epithelial cell' and 'unassigned' cells across individual samples from both normal and primary tumor breast tissue conditions. Given that 'Epithelial cell' is identified as the tumor origin cell type, this analysis provides insights into the genomic stability of these crucial cell populations in the context of breast cancer development.
Visual Summary
The stacked bar plot effectively illustrates the ploidy distribution within the combined "Epithelial cell and unassigned" population for each sample, separated by condition.
- Normal Condition: All four normal samples (Patient_3_4AF75L_RNA, Patient_2_49CFCL_RNA, Patient_1_49758L_RNA, Patient_4_4B146L_RNA) exhibit an overwhelmingly diploid ploidy profile, with nearly 100% of the cells classified as Diploid (light orange bars). A minuscule fraction of Aneuploid cells is barely visible in one sample, indicating high genomic stability in normal breast tissue.
- Primary Tumor Condition: In stark contrast, primary tumor samples display a highly variable and often substantial proportion of Aneuploid cells (maroon bars).
- Many tumor samples, such as Patient_11_3FC..., Patient_6_4C2..., Patient_5_35A..., Patient_12_44F..., and Patient_8_3B2..., show a dominant Aneuploid population, ranging from approximately 70% to nearly 100% of the cells.
- Other tumor samples, like Patient_13_3D3..., Patient_7_35E..., Patient_9_3B3..., and Patient_10_3C7..., present a mixed profile, with Aneuploid cells constituting around 30-40% of the population, alongside a significant Diploid fraction.
- A few tumor samples, such as Patient_15_45C..., Patient_14_43E..., and Patient_14_43E7CL_RNA, show a lower proportion of Aneuploid cells (ranging from ~15% to ~27%), with Diploid cells still making up the majority.
- The 'Unclear' ploidy status (light green bars) is present in both normal and tumor samples but generally constitutes a minor fraction (<10%) of the cells.
Biological Interpretation
The observed ploidy patterns strongly correlate with the pathological state of the tissue, providing critical biological insights:
- Genomic Instability in Cancer: The striking shift from predominantly diploid cells in normal tissue to a significant presence of aneuploid cells in primary tumors is a hallmark of cancer. Aneuploidy, or the presence of an abnormal number of chromosomes, is a direct consequence of genomic instability, a fundamental characteristic of malignant transformation and tumor evolution PubMed search: aneuploidy cancer hallmark.
- Tumor Origin Cell Type: Since 'Epithelial cell' is designated as the tumor origin cell type in this dataset (breast tissue), the high proportion of aneuploid cells in primary tumor samples is highly indicative of malignant epithelial cells. These cells have undergone chromosomal alterations that drive their uncontrolled proliferation and acquisition of cancer characteristics.
- Inter-tumor Heterogeneity: The substantial variability in the proportion of aneuploid cells among different primary tumor samples highlights the genetic heterogeneity inherent in breast cancer. This suggests that different tumors may be at various stages of genomic evolution, possess differing levels of chromosomal instability, or have distinct cellular compositions regarding the proportion of malignant epithelial cells.
- Mixed Cell Populations: The presence of diploid cells within primary tumor samples could represent several possibilities:
- Non-malignant epithelial cells that are part of the tumor microenvironment.
- Earlier-stage cancer cells that have not yet accumulated extensive chromosomal changes.
- Other stromal cells or immune cells within the 'unassigned' category that are naturally diploid.
- The 'unassigned' cell population, when filtered alongside 'Epithelial cell', contributes to the overall ploidy profile. While we cannot disentangle the specific ploidy of 'unassigned' from 'Epithelial' cells in this plot, any aneuploidy observed within this combined population in tumor samples is predominantly attributed to the malignant epithelial cells.
Clinical or Translational Implications
The findings from this ploidy analysis have several important clinical and translational implications for breast cancer:
- Diagnostic Biomarker: Aneuploidy in epithelial cells serves as a robust diagnostic indicator of malignancy in breast tissue. The detection of a significant aneuploid population can help differentiate cancerous lesions from benign conditions GeneCards: Aneuploidy.
- Prognostic and Predictive Value: The proportion and degree of aneuploidy in tumor cells can be a prognostic factor, potentially correlating with tumor aggressiveness, metastatic potential, and recurrence risk in breast cancer. Tumors with a higher percentage of aneuploid cells or more complex karyotypes might indicate a more aggressive disease course or a differential response to certain chemotherapeutic agents PubMed search: aneuploidy breast cancer prognosis.
- Understanding Tumor Evolution: Monitoring ploidy status through single-cell analysis provides insights into the genomic evolution and heterogeneity of breast tumors, which can inform personalized treatment strategies.
- Stratification for Therapy: Identifying the ploidy status could contribute to patient stratification for therapies targeting specific aspects of genomic instability or cell cycle control, especially for highly aneuploid tumors.
11. Cell-Cell Interaction Patterns in Primary Breast Tumors
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interaction (CCI) patterns within the primary breast tumor microenvironment. Using single-cell RNA-seq data, CellPhoneDB was applied to identify significant ligand-receptor interactions between various cell types, including the tumor-origin Epithelial cells (further delineated by ploidy status into Diploid and Aneuploid), Fibroblasts, Macrophages, and T cells (CD4+ and CD8+). The visualization highlights the top 80 significant interactions based on p-value and interaction strength (mean expression) specifically within the primary tumor condition, providing insights into the complex communication network driving tumor biology.
Visual Summary
The dot plot displays a complex landscape of cell-cell interactions within primary breast tumors.
- Interaction Density and Strength: A high density of significant interactions (small dots, dark color representing strong significance) is observed across multiple cell-cell pairs and ligand-receptor complexes. The color intensity of the dots indicates the mean expression level of the interacting ligand-receptor pair, with brighter yellow indicating higher average expression.
Prominent Interacting Cell Types:
- Fibroblast-Epithelial Cell Interactions: Fibroblasts show extensive interactions with both Diploid and Aneuploid Epithelial cells. Many of these interactions involve integrin complexes (e.g., COL1A1-integrin_a2b1_complex, COL1A2-integrin_a1b1_complex, FN1_integrin_a3b1_complex, LAMC1_integrin_a2b1_complex) and collagen-related interactions.
- Epithelial-Epithelial Interactions: Significant interactions are observed between Diploid and Aneuploid Epithelial cells, and also within Aneuploid Epithelial cells (Aneuploid Epi|Aneuploid Epi) and Diploid Epithelial cells (Diploid Epi|Diploid Epi). These include integrin, collagen, and WNT family interactions (e.g., WNT2-SFRP1, WNT4-SFRP2, WNT5A-SFRP4).
- Macrophage Interactions: Macrophages exhibit strong interactions among themselves (Mac|Mac) and with Fibroblasts (Mac|Fib) and Epithelial cells (Mac|Diploid Epi, Mac|Aneuploid Epi). Key interactions involve chemokines (e.g., CCL3L1-CCR1, CCL3-CCR1) and growth factors (e.g., EDN1-EDNRA/B).
- T Cell Interactions: T cells (CD4+ and CD8+) primarily interact with Fibroblasts (Fib|T CD8+, Fib|T CD4+) and Aneuploid Epithelial cells (Aneuploid Epi|T CD4+). Immune checkpoint-related molecules like TIGIT, as well as integrins, are noted in these interactions.
- Ploidy-Specific Differences: Aneuploid Epithelial cells, which represent the likely malignant population, show distinct interaction patterns compared to Diploid Epithelial cells. For instance, Aneuploid Epithelial cells engage in more unique interactions involving WNT family members (WNT2/4/5A-SFRPs) and specific integrin complexes.
- Key Ligand-Receptor Families: Integrins (e.g., various COLxx-integrin and FN1-integrin complexes), Collagens, Chemokines (CXCLs, CCLs), WNT family members, Prostaglandin E2 receptors (PTGES3), and growth factors (EGFR, FGFR1, EDNRA/B) are highly represented among the significant interactions.
Biological Interpretation
The observed CCI patterns reveal critical communication axes within the breast tumor microenvironment that likely contribute to tumor progression, immune evasion, and stromal remodeling.
- Tumor-Stroma Crosstalk (Epithelial-Fibroblast): The prominent integrin and collagen interactions between Epithelial cells (both Diploid and Aneuploid) and Fibroblasts underscore the central role of the extracellular matrix (ECM) and mechanosignaling in breast cancer. Fibroblasts, often reprogrammed into Cancer-Associated Fibroblasts (CAFs), deposit and remodel the ECM, which in turn influences tumor cell proliferation, survival, migration, and resistance to therapy via integrin signaling. Interactions like FN1-integrin_a3b1_complex and various COL-integrin complexes are canonical pathways for cell-matrix adhesion and signaling [GeneCards: Integrin alpha 3; GeneCards: Fibronectin 1].
Immune Cell Recruitment and Modulation:
- Macrophage Activity: The extensive macrophage interactions, particularly via chemokines like CCL3/CCL3L1 with CCR1, indicate their significant role in immune cell recruitment and establishment of an inflammatory TME [PubMed: Chemokines in Cancer]. Macrophages are often polarized to a pro-tumorigenic M2-like phenotype in tumors (Tumor-Associated Macrophages, TAMs), and these interactions could facilitate their accumulation and function. EDN1-EDNRA/B interactions also point to endothelin signaling, which can promote tumor growth and angiogenesis [GeneCards: EDN1].
- T Cell Engagement: T cell interactions with Fibroblasts and Aneuploid Epithelial cells highlight how immune cells are potentially recruited, activated, or suppressed within the TME. The presence of TIGIT suggests a potential immune checkpoint axis, where TIGIT expression on T cells can contribute to their exhaustion, especially when interacting with PVR (CD155) or PVRL2 (CD112) on tumor cells or stromal cells [PubMed: TIGIT immune checkpoint].
- Intratumoral Heterogeneity and Malignancy: The distinction between Diploid and Aneuploid Epithelial cells in their interaction profiles is biologically significant. Aneuploidy is a hallmark of cancer, and the unique interactions observed for Aneuploid Epithelial cells (e.g., specific WNT ligand/SFRP interactions, different integrin subsets) may reflect their acquired aggressive properties, such as enhanced growth, survival, and metastatic potential. WNT signaling is a crucial pathway for cell proliferation and stemness, often hijacked in cancer [GeneCards: WNT].
Other Key Pathways:
- Prostaglandin Signaling: Interactions involving Prostaglandin E2 (PGE2) and its receptors (PTGES3) can modulate inflammation, immunity, and angiogenesis, often favoring tumor progression in the TME [PubMed: Prostaglandins in cancer].
- "Don't Eat Me" Signals: While not explicitly prominent for all cell types in this subset, the broader context of cancer often involves interactions like CD47-SIRPA to evade phagocytosis by macrophages [PubMed: CD47 SIRPA Cancer].
- Growth Factor Signaling: Interactions involving EGFR and FGFR1 suggest paracrine and autocrine loops that drive proliferation and survival of tumor and stromal cells.
Clinical or Translational Implications
The identified cell-cell interaction patterns offer several avenues for clinical and translational applications in breast cancer.
Therapeutic Target Prioritization:
- Integrin and ECM Targeting: Given the extensive integrin-mediated interactions between Fibroblasts and Epithelial cells, targeting specific integrin heterodimers (e.g., alphaVbeta3, alpha5beta1) or enzymes involved in ECM remodeling could disrupt tumor growth, invasion, and metastasis [PubMed: Integrins cancer therapy].
- Immune Checkpoint Blockade: The presence of TIGIT interactions suggests that targeting TIGIT, potentially in combination with other immune checkpoint inhibitors, could be a strategy to reactivate anti-tumor T cell responses in breast cancer patients [PubMed: TIGIT cancer clinical trials].
- WNT Pathway Modulators: Interactions involving WNT ligands and SFRPs, particularly those distinct in Aneuploid Epithelial cells, highlight the WNT pathway as a potential therapeutic target, especially for tumors driven by aberrant WNT signaling.
- Chemokine Receptor Blockade: CCR1 (receptor for CCL3/CCL3L1) could be a target to reduce macrophage infiltration into tumors and subsequently limit their pro-tumorigenic functions.
- Biomarker Discovery: Specific ligand-receptor pairs with high activity in the primary tumor, especially those distinguishing Aneuploid Epithelial cells, could serve as prognostic biomarkers for disease aggressiveness or predictive biomarkers for response to targeted therapies.
- Combination Therapies: Understanding the intricate network of interactions could guide the development of rational combination therapies, for example, combining ECM-targeting agents with immunotherapies or WNT pathway inhibitors.
- Monitoring Treatment Response: Changes in these CCI patterns could be monitored in liquid biopsies or repeat tumor biopsies to assess treatment efficacy and detect resistance mechanisms.
12. Primary Breast Tumor Cell-Cell Interaction Analysis
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interactions (CCI) within the primary breast tumor microenvironment using single-cell RNA sequencing data. The dot plot visualizes the most significant and highly expressed ligand-receptor pairs between different cell populations present in the primary_tumor condition. Interactions are filtered for a p-value cutoff of 0.05 and a mean expression cutoff of 0.01, displaying up to 80 prominent interactions. The size of the dots represents the statistical significance (as -log10(p-value)), and the color indicates the interaction strength (as log2(mean expression)). The analysis specifically includes interactions involving 'Aneuploid Epithelial' and 'Diploid Epithelial' cells, given that 'Epithelial cell' is identified as the tumor origin cell type and ploidy_dec distinguishes these populations.
Visual Summary
The visualization reveals a highly active and complex network of cell-cell communications within the primary breast tumor.
- Dominant Interaction Partners: Fibroblasts (Fib) and Endothelial cells (Endo) emerge as key communicators, engaging in numerous interactions with other stromal components (Fib, SMC, Endo), immune cells (Mac, T cells), and crucially, with both Diploid and Aneuploid Epithelial cells.
- Ploidy-Specific Interactions: Aneuploid Epithelial cells, likely representing the malignant tumor cells, demonstrate robust interactions, particularly with Fibroblasts and Endothelial cells. These interactions are often highly significant (large dot size) and involve considerable expression levels (bright green/yellow colors). While Diploid Epithelial cells also show interactions, the prominent involvement of Aneuploid Epithelial cells in strong signaling axes is notable.
Key Ligand-Receptor Families:
- Integrin complexes: These are by far the most abundant interactions, involving various collagen (COL) and fibronectin (FN1) ligands with integrin receptors. These interactions span almost all major cell-pair categories, especially Fibroblast-Epithelial, Fibroblast-Endothelial, and Endothelial-Epithelial cell communications.
- Growth Factor/Angiogenesis pathways: PGF-FLT1 (and PGF-NRP1) and VEGF-VEGFR2 interactions are prominent, notably originating from Fibroblasts and Endothelial cells, and targeting Epithelial cells and Endothelial cells.
- Chemokine Signaling: CXCL12-CXCR4 is a notable interaction, particularly between Fibroblasts (Fib|Fib) and Macrophages (Mac|Fib, Mac|Mac). CCL2-CCR1 and CCL3L1-CCR1 are also observed, mainly involving Macrophages and Epithelial cells.
- WNT Signaling: Several WNT ligand-SFRP receptor interactions are present, though generally with lower mean expression values compared to integrins or growth factors.
- IL6-IL6 receptor: This interaction is also observed in several cell pairs.
Biological Interpretation
The observed cell-cell interactions provide critical insights into the biological processes driving primary breast tumor progression and shaping the tumor microenvironment (TME).
- ECM Remodeling and Tumor Cell-Stroma Adhesion (Integrins): The widespread integrin-mediated interactions underscore the profound importance of extracellular matrix (ECM) remodeling and cell adhesion in breast cancer. Fibroblasts, acting as cancer-associated fibroblasts (CAFs), secrete collagen and fibronectin, which then interact with integrins on both tumor epithelial cells and other stromal cells (endothelial cells). This interaction network facilitates tumor cell migration, invasion, survival, and resistance to therapy, and is fundamental to the structural and functional integrity of the TME. GeneCards: Integrin alpha family, GeneCards: Collagen family
- Angiogenesis (PGF-FLT1, VEGF-VEGFR2): The strong PGF-FLT1 (and PGF-NRP1) and VEGF-VEGFR2 interactions, particularly between Fibroblasts/Endothelial cells and Epithelial cells, are hallmarks of active angiogenesis. Placental growth factor (PGF) and Vascular Endothelial Growth Factor (VEGF) are potent pro-angiogenic factors that promote the formation of new blood vessels, essential for providing nutrients and oxygen to the rapidly growing tumor, and for facilitating metastasis. This robust signaling indicates a highly pro-angiogenic TME in primary breast tumors. PubMed Search: PGF angiogenesis cancer, PubMed Search: VEGF angiogenesis cancer
- Immune Cell Recruitment and Stromal Interaction (Chemokines):
- CXCL12-CXCR4: The prominent interactions between Fibroblasts (Fib|Fib, Mac|Fib) mediated by CXCL12-CXCR4 highlight its role in orchestrating stromal cell function and immune cell recruitment. In breast cancer, the CXCL12-CXCR4 axis is known to attract regulatory T cells, myeloid-derived suppressor cells, and promote fibroblast activation, contributing to an immunosuppressive and pro-metastatic TME. GeneCards: CXCL12
- CCL2-CCR1/CCL3L1-CCR1: These macrophage-epithelial interactions suggest active recruitment and polarization of macrophages (e.g., M2-like tumor-associated macrophages) within the tumor, which can promote tumor growth, immune suppression, and angiogenesis.
- Pro-inflammatory and Pro-tumorigenic Signaling (IL6-IL6R): The presence of IL6-IL6 receptor interactions indicates an active inflammatory component within the primary tumor microenvironment. IL-6 is a pleiotropic cytokine that can drive tumor cell proliferation, survival, angiogenesis, and immune evasion in breast cancer. GeneCards: IL6
- Aneuploid Epithelial Cells as Drivers: The active participation of Aneuploid Epithelial cells in a broad range of strong interactions, particularly with Fibroblasts and Endothelial cells, supports their role as the primary malignant population actively co-opting the microenvironment for growth and survival. The interactions with stromal cells (e.g., integrins, PGF-FLT1) are critical for their malignant phenotype.
Clinical or Translational Implications
The identified cell-cell interactions offer compelling insights for therapeutic targeting and experimental validation in breast cancer.
- Targeting Integrin-Mediated Adhesion: Given the pervasive role of integrins in mediating interactions between tumor cells (Aneuploid Epithelial) and the TME (Fibroblasts, Endothelial cells), integrin inhibitors represent a promising class of therapeutic agents to disrupt tumor cell adhesion, migration, and invasion. Experimental validation could involve *in vitro* assays of tumor cell migration/invasion in 3D co-culture models with CAFs, and *in vivo* studies using integrin-blocking antibodies to assess their impact on primary tumor growth and metastasis.
- Anti-Angiogenic Strategies: The strong PGF-FLT1 and VEGF-VEGFR2 signaling pathways highlight the importance of angiogenesis in primary breast tumors. Existing anti-VEGF therapies (e.g., bevacizumab) or novel inhibitors targeting PGF or FLT1 could be investigated, potentially in combination with other agents, to effectively curb tumor angiogenesis and growth. Clinical trials could evaluate their efficacy in breast cancer patients with similar CCI profiles. PubMed Search: Anti-angiogenic therapy breast cancer
- Modulating Immune and Stromal Communications: The CXCL12-CXCR4 axis represents a potential target to alter the immunosuppressive and pro-metastatic TME. CXCR4 antagonists could be explored to reduce recruitment of immunosuppressive cells and inhibit metastasis. Similarly, targeting CCL2-CCR1 could modulate macrophage infiltration and polarization. Experimental validation would involve assessing the impact of such interventions on immune cell composition and function within the TME, as well as tumor growth and metastasis.
- IL-6 Pathway Inhibition: Given the pro-tumorigenic role of IL-6, inhibitors of IL-6 or its receptor could be explored, particularly in patients exhibiting high IL-6 signaling.
- Biomarker Development: The specific ligand-receptor pairs identified as highly active could serve as potential biomarkers for patient stratification, predicting response to targeted therapies, or identifying patients at higher risk of aggressive disease. Further research is needed to correlate these CCI patterns with clinical outcomes.
13. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Related Genes in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interactions (CCI) using CellPhoneDB results derived from single-cell RNA-seq data of human breast tissue, comparing normal and primary tumor conditions. The analysis specifically filters for a predefined list of genes associated with immune checkpoint pathways and cell cycle regulation. The plot_cci_dots tool visualizes significant ligand-receptor interactions between different cell types, with dot size representing the statistical significance (-log10(p-value)) and dot color indicating the interaction strength (log2(mean expression)). A key aspect of this analysis is the differentiation between Diploid Epi (diploid epithelial cells) and Aneuploid Epi (aneuploid epithelial cells, representing the likely malignant population in the tumor context, as Epithelial cell is the tumor origin celltype).
Visual Summary
Comparison of Normal vs. Primary Tumor:
- Overall Complexity and Strength: The primary tumor microenvironment exhibits a noticeably more complex and generally stronger network of cell-cell interactions compared to normal tissue. Many more significant interactions (larger and darker dots) are observed in the tumor setting.
- Emergence of Aneuploid Epithelial Cells: Aneuploid Epi cells, which are not present in the normal tissue, become a central hub of interactions in the primary tumor. They engage in extensive autocrine (self-interactions) and paracrine interactions with various stromal and immune cell types.
- Dominant Ligand-Receptor Families: Both conditions show significant interactions involving Growth Factor Receptors (EGFR family: AREG_EGFR, HBEGF_EGFR, EREG_EGFR, TGFA_EGFR) and the Transforming Growth Factor-beta (TGF-beta) pathway (TGFB1/2/3 with their respective receptors, and TGFB1_integrin_aVb6_complex). In the tumor, these pathways appear significantly upregulated and diversified in their cellular engagement.
- Immune Cell Engagement: In the primary tumor, there is a clear increase in interactions involving immune cells such as T cells (T CD8+, T CD4+), Macrophages (Mac), and Mast cells with both Aneuploid Epi and various stromal components. While direct, canonical immune checkpoint receptor-ligand pairs like PD-1/PD-L1 (PDCD1/CD274) were included in the gene list, they are not prominently displayed as highly significant interactions in these plots. However, other immune-related interactions (e.g., CD86_CD28, LCK_CD8_receptor, CD83_IFNGR1) are observed.
Specific Observations by Condition:
Normal Tissue CCI:
- Diploid Epi cells show strong autocrine (Diploid Epi|Diploid Epi) and paracrine interactions with Endothelial cells (Diploid Epi|Endo, Endo|Diploid Epi). These interactions are largely mediated by TGFB1/2/3 and their receptors, and AREG_EGFR/HBEGF_EGFR. This suggests active growth factor signaling crucial for maintaining epithelial and endothelial homeostasis.
- Endothelial cells also show strong self-interactions and crosstalk with Fibroblasts and Smooth muscle cells, again largely through TGF-beta and EGFR signaling.
- ILC cells interact with Fibroblasts and Smooth muscle cells, highlighting immune-stromal communication even in healthy tissue.
Primary Tumor Tissue CCI:
- Aneuploid Epithelial Cells as Key Players: Aneuploid Epi cells exhibit extremely strong autocrine signaling, particularly via TGFB1_TGFbeta_receptor1, TGFB2_TGFbeta_receptor2, TGFB3_TGFbeta_receptor3, and TGFA_EGFR. This indicates robust self-sustaining growth and differentiation signals.
- Tumor-Stromal Crosstalk: Aneuploid Epi cells engage in strong heterotypic interactions with Endothelial cells (Aneuploid Epi|Endo, Endo|Aneuploid Epi), Fibroblasts (Fib|Aneuploid Epi), and Smooth muscle cells (Aneuploid Epi|SMC). TGFB signaling is overwhelmingly dominant in these interactions, along with EREG_EGFR. This points to extensive reprogramming of the tumor microenvironment (TME) driven by the malignant cells.
- Tumor-Immune Cell Interactions: Macrophages (Mac) show strong interactions with Aneuploid Epi cells (Mac|Aneuploid Epi), often mediated by TGFB ligands and receptors. T cells (T CD8+, T CD4+) also show interactions with Aneuploid Epi, Endothelial cells, and Fibroblasts. Mast cells interact with Aneuploid Epi and Endothelial cells.
- Specific Immune-Related Signals: CD86_CD28 interactions are observed between Fibroblasts and Epithelial cells (both Diploid and Aneuploid), and Endothelial cells. LCK_CD8_receptor interactions are seen involving T CD8+ cells and stromal cells. CD83_IFNGR1 is observed between Endothelial cells and Aneuploid Epi cells, suggesting interferon-gamma signaling influencing the tumor-endothelial interface.
Biological Interpretation
The analysis reveals a profound shift in cellular communication within the breast tissue transitioning from a normal to a primary tumor state, particularly when focusing on genes related to immune checkpoints and cell cycle regulation.
- TGF-beta Signaling as a Central Driver of Tumor Microenvironment Remodeling: The consistent and strong activation of TGF-beta signaling across numerous cell-cell interfaces in the primary tumor is a critical finding. In the normal tissue, TGF-beta primarily mediates homeostatic epithelial-endothelial and stromal interactions. However, in the tumor, Aneuploid Epi cells become key producers and responders to TGF-beta, engaging in autocrine loops and paracrine interactions with Endothelial cells, Fibroblasts, and Macrophages. This is highly relevant as TGF-beta is a pleiotropic cytokine with dual roles: initially tumor-suppressive, but later promoting tumor progression by fostering epithelial-mesenchymal transition, enhancing angiogenesis, suppressing anti-tumor immunity, and driving desmoplasia [PMID: 32669614]. The strong Mac|Aneuploid Epi interactions via TGF-beta suggest potential M2-like macrophage polarization, contributing to an immunosuppressive TME.
- Altered EGFR Signaling in Tumor Progression: While EGFR signaling is present in normal breast tissue, its ligand repertoire and interacting partners change in the primary tumor. The emergence of EREG_EGFR interactions and its involvement with Aneuploid Epi suggests a specific activation of the EGFR pathway that supports tumor cell proliferation and survival. EGFR is a well-established oncogenic driver, and its altered signaling profile in Aneuploid Epi highlights its role in malignant transformation and progression [GeneCards: EGFR].
- Complex Immune Cell Crosstalk in the TME: The primary tumor environment shows a significant increase in interactions involving various immune cell types (T cells, Macrophages, Mast cells) with tumor cells and stromal components. While direct PD-1/PD-L1 interactions were not highlighted as top signals in this specific analysis, the presence of CD86_CD28 interactions, even if primarily stromal, indicates costimulatory molecule engagement. LCK_CD8_receptor and CD83_IFNGR1 interactions point to T cell receptor signaling and interferon pathway engagement, respectively, at the tumor-stromal-immune interfaces. The overall increase in immune cell interactions, particularly those involving Macrophages and T cells with Aneuploid Epi cells often through TGFB signaling, suggests a dynamic, yet potentially immunosuppressive, immune landscape characteristic of many solid tumors.
- Role of Cell Cycle Regulators (Indirectly via Growth Factors): Many of the filtered "cell cycle" genes are intracellular effectors (CDKs, cyclins, MCMs). Their influence on cell-cell communication is primarily indirect, by modulating the expression or activity of growth factor receptors or their ligands. The observed upregulation of EGFR and TGF-beta signaling directly impacts cell proliferation and cell cycle progression in the tumor cells, illustrating how external signals from the TME can drive aberrant cell cycle activity in cancer.
Clinical or Translational Implications
The observed patterns of cell-cell interactions have significant clinical and translational implications, particularly for therapeutic targeting and understanding tumor biology.
- TGF-beta Pathway as a Promising Therapeutic Target: The widespread and robust TGF-beta signaling in the primary tumor, particularly involving Aneuploid Epi cells, stromal, and immune cells, positions the TGF-beta pathway as a high-priority therapeutic target. Inhibiting TGF-beta signaling could disrupt multiple pro-tumorigenic processes, including tumor cell proliferation, immune evasion, and fibrosis. Various agents targeting TGF-beta, such as receptor kinase inhibitors or ligand traps, are currently under investigation for cancer treatment [PubMed search: TGF-beta inhibitor cancer therapy].
- EGFR Pathway Targeting in Aneuploid Epithelial Cells: The strong EGFR signaling, especially involving EREG_EGFR with Aneuploid Epi cells, suggests that these malignant cells may be susceptible to EGFR inhibitors. Further validation could determine if specific EGFR inhibitors (e.g., gefitinib, erlotinib, or afatinib) could be effective in a subset of breast cancer patients characterized by this signaling profile [GeneCards: EGFR].
- Modulating the Tumor-Immune Microenvironment: The extensive immune-stromal-tumor interactions, particularly the role of TGF-beta in macrophage-tumor crosstalk, highlight the potential for combination therapies that target both tumor cell intrinsic pathways and the immunosuppressive TME. For instance, combining TGF-beta inhibitors with immune checkpoint blockade could potentially overcome resistance mechanisms and enhance anti-tumor immunity by reprogramming the TME and reversing immune suppression [PubMed search: TGF-beta immune checkpoint blockade combination].
- Biomarker Discovery: The specific ligand-receptor pairs identified as highly active in the primary tumor, such as TGFB1_TGFbeta_receptor1 or EREG_EGFR on Aneuploid Epi cells, could serve as potential biomarkers for patient stratification or response prediction to targeted therapies. Further studies could investigate their expression levels and functional relevance in patient samples.
14. Condition-Specific Cell-Cell Interaction Patterns in Breast Cancer
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates statistically significant differences in cell-cell interactions (CCI) between normal breast tissue and primary breast tumors, focusing on major immune and stromal cells. The dot plot visualizes the strength (standardized mean, color intensity) and statistical significance (-log10(p), dot size) of various ligand-receptor pairs (CCI indices) across individual patient samples within each condition. This approach helps identify specific intercellular communication pathways that are dysregulated in the tumor microenvironment.
Visual Summary
The dot plot clearly differentiates CCI patterns between normal and primary tumor samples:
- Normal Tissue Specificity: In normal samples (e.g., Patient_1 to Patient_4), a distinct set of interactions is observed. These include ligand-receptor pairs such as CCL2_ACKR1--Fib|Endo, CD320_JAML--Endo|ILC, CXCL1_ACKR1--Fib|Endo, and ProstaglandinE2_byPTGES2_PTGER3--Epi(Dip)|Fib. Interactions involving TNFSF10 (TRAIL) and its receptors TNFRSF10A/B with Epithelial (Diploid) cells and Fibroblasts are also notable in normal samples. These interactions generally show moderate to high strength and significance in a subset of normal samples.
- Primary Tumor Dominance of ECM-Integrin Signaling: In stark contrast, primary tumor samples exhibit a significantly higher number and intensity of strong, highly significant cell-cell interactions. A striking pattern emerges, dominated by interactions involving extracellular matrix (ECM) components like COL6A1, COL6A2, COL6A3, COL18A1 (Collagen VI family and Collagen XVIII) and FN1 (Fibronectin) with various Integrin receptor complexes (e.g., integrin_a1b1_complex, integrin_a2b1_complex, integrin_aVb1_complex, integrin_aVb5_complex, integrin_a5b1_complex).
- Cell Type Involvement in Tumor: These highly active ECM-integrin interactions predominantly occur between Fibroblasts (Fib) and Endothelial cells (Endo), and sometimes involve Smooth Muscle Cells (SMC).
- Widespread Tumor Activity: The robust presence of these ECM-integrin interactions across almost all primary tumor samples suggests a highly conserved and pervasive mechanism within the tumor microenvironment, distinguishing it sharply from normal tissue.
Biological Interpretation
The observed differences highlight a profound remodeling of the cellular communication landscape in primary breast tumors compared to normal tissue.
- Tumor Microenvironment Remodeling by ECM-Integrin Axis: The most prominent finding is the massive upregulation of interactions centered around collagens, fibronectin, and integrins in primary tumors.
- Extracellular Matrix (ECM) Components: Collagen VI (COL6A1, COL6A2, COL6A3) and Fibronectin (FN1) are key components of the ECM. Their overexpression and deposition are hallmarks of many cancers, including breast cancer, where they contribute to tissue stiffness, altered signaling, and create a permissive environment for tumor growth and metastasis. PubMed search: Collagen VI cancer integrin, GeneCards: FN1
- Integrin Receptors: Integrins are critical transmembrane receptors that link the ECM to the intracellular cytoskeleton, mediating cell adhesion, migration, proliferation, and survival. The activation of various integrin complexes (e.g., α1β1, α2β1, αVβ1, αVβ5, α5β1) on stromal (Fibroblasts, Smooth Muscle Cells) and endothelial cells indicates increased mechanotransduction and signaling from the altered tumor ECM. These specific integrin subtypes are known to be involved in cancer progression, angiogenesis, and invasion. PubMed search: Integrin cancer progression
- Cancer-Associated Fibroblasts (CAFs): The frequent involvement of Fibroblasts in these ECM-integrin interactions strongly suggests the presence and activation of CAFs. CAFs are a major component of the tumor stroma, known for their role in depositing and remodeling the ECM, secreting growth factors, and promoting tumor progression, invasion, and metastasis. PubMed search: Cancer-Associated Fibroblasts ECM integrin
- Endothelial Cells and Angiogenesis: Interactions with Endothelial cells via integrins are crucial for angiogenesis (new blood vessel formation), a process vital for tumor survival and growth, by facilitating endothelial cell migration and differentiation. PubMed search: Integrin Endothelial Angiogenesis
- Normal Tissue Homeostasis and Surveillance: The interactions observed in normal tissue likely reflect physiological processes.
- Immune Surveillance/Homeostasis: Interactions like CCL2-ACKR1 and CD320-JAML might be involved in basal immune cell trafficking and regulation. TNFSF10 (TRAIL) interactions with its receptors on epithelial (diploid) cells and fibroblasts suggest a role in physiological cell turnover or immune surveillance to remove potentially aberrant cells. GeneCards: TNFSF10
- Self-Recognition: The SIRPA-CD47 interaction, commonly exploited by cancer cells for immune evasion, is also essential for maintaining self-tolerance and preventing phagocytosis of healthy cells by immune cells in normal tissue. GeneCards: CD47
Clinical or Translational Implications
- Therapeutic Targets: The pronounced activation of ECM-integrin interactions in primary tumors presents a promising avenue for therapeutic intervention. Targeting specific integrin receptors (e.g., αVβ1, αVβ5, α5β1) or molecules involved in the synthesis or deposition of COL6A1/2/3 and FN1 could disrupt tumor progression, invasion, and metastasis by remodeling the tumor microenvironment and inhibiting pro-tumorigenic signaling in CAFs and endothelial cells.
- Biomarkers: The distinct patterns of CCI, particularly the strong ECM-integrin signature, could serve as a valuable diagnostic or prognostic biomarker for breast cancer, helping to distinguish malignant tissue from normal tissue, or to assess tumor aggressiveness.
- Understanding Tumor Progression: This analysis provides critical insight into the complex interplay between tumor cells (Epithelial), stromal cells (Fibroblasts, Smooth Muscle Cells), and endothelial cells, underscoring the importance of targeting the entire tumor ecosystem, not just the malignant cells, for effective cancer therapy.
15. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies condition-specific surfaceome markers for Epithelial cells from human breast tissue, comparing cells derived from "Diploid" samples (representing normal tissue, given the reference condition for DEG is 'normal' and the sample grouping) versus "primary_tumor" samples. The dot plot visualizes the expression of up to 50 top surfaceome markers per condition, showing both the fraction of cells expressing each marker (dot size) and the mean expression level within expressing cells (dot color intensity). The goal is to identify unique surface markers that distinguish normal epithelial cells from tumor epithelial cells, which can have implications for diagnosis and targeted therapies.
Visual Summary
The dot plot is organized to show samples (rows) grouped first by ploidy inference ("Diploid" for the upper cluster, which represents normal tissue epithelial cells in this context) and then by condition ("primary_tumor" for the lower cluster, representing tumor epithelial cells). The columns represent individual surfaceome genes.
- Diploid (Normal-like) Epithelial Cells: A distinct set of markers, including PRNP, EGFR, GYPC, TSPAN13, and TMEM219, show higher expression and prevalence in the "Diploid" samples. These markers are strongly expressed across most "Diploid" samples, indicating their consistent presence in normal-like epithelial cells.
- Primary Tumor Epithelial Cells: A different and more extensive panel of markers, such as CRB3, TMCO3, ERBB3, TNFRSF10, BST2, ADAM15, ALCAM, CA12, PTPRA, IGSF8, SIGIRR, BCAM, SLC44A4, GPR137B, and GPR160, exhibit strong and prevalent expression exclusively or predominantly in the "primary_tumor" samples. Several of these genes show very high mean expression (dark red dots) and a large fraction of expressing cells (large dots) across multiple tumor samples.
- Overlap and Specificity: There is a clear segregation of markers between the two conditions. Markers like PRNP and EGFR appear largely restricted to the normal-like epithelial cells (Diploid group), while genes like CRB3, ERBB3, and CA12 are highly specific to primary tumor epithelial cells.
- Sample Variability: Within both the "Diploid" and "primary_tumor" groups, there is some variability in marker expression across different patient samples, indicating inter-patient heterogeneity, as expected in cancer.
- Cell Counts: The bar plot on the right indicates the number of epithelial cells per patient sample included in the analysis, ranging from 67 to 3954 cells.
Biological Interpretation
The analysis highlights significant differences in the surface proteome of epithelial cells between normal-like (diploid) and primary tumor conditions in breast tissue. These differences reflect the altered biological state and functions of cancer cells.
- Normal Epithelial Markers: Genes like EGFR (Epidermal Growth Factor Receptor) are crucial for normal epithelial growth and differentiation [GeneCards]. Their presence in normal-like epithelial cells is expected. PRNP (Prion Protein) is involved in cell adhesion, differentiation, and survival [GeneCards].
- Primary Tumor Epithelial Markers: The upregulation of specific surface markers in tumor epithelial cells points to key pathways involved in cancer progression:
- ERBB3 (HER3): A member of the EGFR family, often overexpressed in breast cancer and implicated in tumor growth, survival, and resistance to therapy, particularly when co-expressed with HER2 [GeneCards].
- CA12 (Carbonic Anhydrase XII): Involved in pH regulation and often associated with hypoxic conditions and aggressive tumor phenotypes in various cancers, including breast cancer [GeneCards].
- CRB3 (Crumbs Homolog 3): Plays a role in cell polarity and epithelial integrity. Its altered expression in cancer can impact cell differentiation and invasion [GeneCards].
- BST2 (Bone Marrow Stromal Antigen 2, also known as CD317 or tetherin): An interferon-inducible protein that can regulate immune responses and is expressed on the surface of various tumor cells [GeneCards].
- ADAM15 (ADAM Metallopeptidase Domain 15): A disintegrin and metalloproteinase that can influence cell adhesion, migration, and proteolysis, processes critical for tumor invasion and metastasis [GeneCards].
- ALCAM (Activated Leukocyte Cell Adhesion Molecule, also known as CD166): A cell adhesion molecule implicated in tumor progression and metastasis in various cancers [GeneCards].
- TNFRSF10 (TNF Receptor Superfamily Member 10), potentially indicating alterations in cell death pathways or immune interactions.
- Surfaceome Relevance: The focus on surfaceome markers is critical because these proteins are readily accessible on the cell surface, making them prime candidates for direct therapeutic targeting and non-invasive detection methods. The distinct expression patterns observed here reflect fundamental biological shifts between normal and malignant epithelial states.
Clinical or Translational Implications
The identified condition-specific surfaceome markers in epithelial cells hold significant clinical and translational potential for breast cancer.
- Diagnostic and Prognostic Biomarkers: Markers like ERBB3, CA12, ADAM15, and ALCAM, which are highly specific to primary tumor epithelial cells, could serve as novel diagnostic or prognostic biomarkers. Their detection on circulating tumor cells (CTCs) or in tissue biopsies could aid in early diagnosis, patient stratification, and prediction of disease aggressiveness.
- Therapeutic Targets: The specific overexpression of surface proteins on tumor epithelial cells makes them excellent candidates for targeted therapies.
- ERBB3 is already a known therapeutic target, and its high expression suggests that epithelial cells in these primary tumors might respond to ERBB3-targeting agents (e.g., monoclonal antibodies, antibody-drug conjugates) [PubMed Search].
- Other highly expressed tumor-specific surface markers such as CA12, ADAM15, and ALCAM could be explored as novel targets for developing antibody-drug conjugates (ADCs), bispecific antibodies, or CAR-T cell therapies to selectively kill tumor cells while sparing normal tissues.
- Experimental Validation: These findings warrant further experimental validation.
- Immunohistochemistry (IHC) or immunofluorescence could confirm protein expression patterns in patient tissue samples.
- Flow cytometry could be used to validate cell surface expression on dissociated tumor cells.
- *In vitro* and *in vivo* functional assays could assess the impact of targeting these markers on tumor cell proliferation, survival, and metastatic potential.
- Analysis of larger patient cohorts could solidify their diagnostic, prognostic, or predictive value.
16. Macrophage Condition-Specific Surfaceome Markers in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies and visualizes condition-specific surfaceome markers in Macrophage cells isolated from human breast tissue, comparing normal tissue samples with primary_tumor samples. The dot plot illustrates the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across different patient samples within each condition. Focusing on surfaceome markers is particularly relevant for therapeutic targeting and cell-type characterization.
Visual Summary
The dot plot clearly segregates macrophage surface markers into two distinct groups based on their expression patterns in normal versus primary_tumor conditions.
- Normal-Specific Macrophage Markers: A cluster of markers, including CD163, FPR1, C3AR1, and MPEG1, shows high expression and prevalence in Macrophages from normal breast tissue samples (highlighted by the top-left red box, especially prominent in Patient_4_4B146L_RNA). These markers are generally absent or expressed at very low levels in primary_tumor macrophages.
- Primary Tumor-Specific Macrophage Markers: A much larger group of surface markers is significantly upregulated and highly prevalent in Macrophages from primary_tumor samples (enclosed by the large red box on the right). These include EREG, ITGB8, CD55, CXCR4, MPZL1, CD109, HLA-DRB5, ITGAV, TPRA1, HLA-F, TFPI, SLC44A1, SLC36A4, FURIN, and MET. Their expression is largely absent or low in normal tissue macrophages.
- Patient-to-Patient Variability: While clear condition-specific patterns emerge, there is some variability in expression levels and prevalence across individual patient samples within the primary_tumor group, suggesting potential heterogeneity in tumor-associated macrophage (TAM) populations.
Biological Interpretation
The distinct sets of surface markers highlight the profound functional reprogramming and adaptation of macrophages in response to the tumor microenvironment compared to their roles in normal tissue homeostasis.
Normal Tissue Macrophages:
- CD163 is a well-known scavenger receptor and a classic marker for M2-like macrophages, often associated with anti-inflammatory responses, tissue repair, and immune regulation in healthy tissues UniProt: P16671.
- FPR1 (Formyl Peptide Receptor 1) is involved in host defense and inflammation, mediating immune cell chemotaxis UniProt: P21730.
- C3AR1 (Complement C3a Receptor 1) plays a role in innate immunity and inflammatory responses UniProt: P21860.
- MPEG1 (Macrophage-expressed gene 1) is involved in phagocytosis and innate immune defense.
These markers collectively suggest a macrophage phenotype oriented towards immune surveillance, tissue maintenance, and resolution of inflammation in a healthy state.
Primary Tumor-Associated Macrophages (TAMs):
The broad upregulation of various surface markers in TAMs reflects their multifaceted roles in tumor progression:
- Pro-Tumorigenic Signaling: EREG (Epiregulin) is a growth factor often secreted by TAMs, promoting tumor cell proliferation and survival PubMed search: Epiregulin tumor-associated macrophages breast cancer. MET (MET proto-oncogene) is a receptor tyrosine kinase associated with tumor growth, invasion, and metastasis, whose expression on TAMs can contribute to tumor progression UniProt: P08581.
- Immune Evasion and Remodeling: ITGB8 (Integrin Beta-8) and ITGAV (Integrin Alpha-V) are integrins involved in extracellular matrix interactions and activation of TGF-beta, which can drive immunosuppression and fibrosis within the tumor microenvironment UniProt: P26012. CD55 protects cells from complement-mediated lysis, potentially aiding immune evasion UniProt: P08174.
- Cell Migration and Infiltration: CXCR4 is a chemokine receptor crucial for cell migration and is frequently implicated in metastasis and tumor progression by orchestrating cell movement UniProt: P61073.
- Antigen Presentation and Immune Modulation: HLA-DRB5 and HLA-F are MHC class II-related molecules. While generally associated with antigen presentation, their specific expression patterns on TAMs can be linked to altered T-cell responses and an immunosuppressive phenotype in cancer PubMed search: HLA-DRB5 HLA-F tumor-associated macrophages immunosuppression.
- Metabolic Reprogramming: SLC44A1 and SLC36A4 are solute carrier proteins, suggesting metabolic adaptations in TAMs to meet the energy demands and altered nutrient environment of the tumor UniProt: Q9BXR8, UniProt: Q9NQT2.
- Other Roles: TFPI (Tissue Factor Pathway Inhibitor) is involved in coagulation but also has roles in angiogenesis and tumor growth UniProt: P10646. CD109 has been linked to cancer cell growth and TGF-beta signaling.
This analysis underscores the highly adaptable nature of macrophages, which acquire distinct phenotypes and functions in the tumor microenvironment to promote cancer progression.
Clinical or Translational Implications
The identified condition-specific surfaceome markers in macrophages offer significant clinical and translational potential:
- Biomarkers: The distinct expression patterns of surface proteins like CD163 for normal tissue macrophages and EREG, ITGB8, CXCR4, or MET for TAMs could serve as valuable diagnostic or prognostic biomarkers in breast cancer. These could be assessed via immunohistochemistry or flow cytometry from biopsy samples.
- Therapeutic Targets: Surface markers are prime candidates for targeted therapies due to their accessibility on the cell surface. Targeting pro-tumorigenic TAMs expressing markers like CXCR4, EREG, ITGB8, or MET could involve:
- Monoclonal Antibodies: Therapeutic antibodies could specifically bind to and block the function of these receptors or trigger antibody-dependent cellular cytotoxicity (ADCC) to deplete TAMs.
- Antibody-Drug Conjugates (ADCs): Delivering cytotoxic drugs specifically to TAMs by conjugating them to antibodies against these markers.
- CAR-T/NK Cell Therapy: Engineering immune cells to recognize and eliminate TAMs expressing specific surface markers.
Modulating the activity or depletion of TAMs could reprogram the tumor microenvironment, making it less permissive for tumor growth and potentially more susceptible to other immunotherapies.
- Immunotherapy Enhancement: Understanding the specific surfaceome of TAMs can inform strategies to overcome TAM-mediated immunosuppression, a major hurdle in cancer immunotherapy. For example, blocking CXCR4 could inhibit TAM recruitment to the tumor, while modulating integrin pathways could reduce immunosuppressive TGF-beta activation.
17. Fibroblast Condition-Specific Surfaceome Markers in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify surfaceome markers that are specifically expressed in Fibroblasts under different conditions (normal vs. primary tumor) in human breast tissue. Using single-cell RNA-seq data, the plot_markers_and_expression_dot tool generated a dot plot visualizing the expression patterns of these markers across individual patient samples. The analysis focused on genes encoding surface proteins to identify potential therapeutic targets or biomarkers accessible on the cell surface.
Visual Summary
The dot plot effectively illustrates the differential expression of surfaceome markers in Fibroblasts across various patient samples, categorized by their condition (normal or primary tumor).
- Differential Expression: A clear distinction is observed between Fibroblasts from 'normal' and 'primary_tumor' conditions. Most identified markers, such as FAP, CD276, MMP14, GPNMB, MXRA8, SDC2, ITGB5, NRP2, and DDR2, show significantly higher mean expression (darker red color) and a greater fraction of expressing cells (larger dot size) in the 'primary_tumor' samples compared to 'normal' samples. Conversely, genes like EDNRB and PMEPA1 appear to be more uniformly expressed or less distinctly associated with the tumor condition.
- Patient-level Heterogeneity: While a general pattern of upregulation is evident in tumor samples, there is considerable heterogeneity among individual patients. For example, patients such as Patient_8_3821AL_RNA, Patient_14_43E7CL_RNA, Patient_14_43E7BL_RNA, Patient_12_44F0AL_RNA, and Patient_15_45CB0L_RNA (highlighted by the red box) exhibit consistently high expression of a broad range of these markers, suggesting a robust tumor-associated fibroblast phenotype. Other tumor patients (e.g., Patient_10_3C7D1L_RNA) show less pronounced upregulation for some markers.
- Cell Count Information: The bar chart on the right indicates the number of Fibroblast cells captured for each patient sample. Samples with higher cell counts generally show clearer expression patterns, though marker detection is not solely dependent on cell numbers.
Biological Interpretation
The identified surfaceome markers provide strong biological insights into the distinct roles and activation states of Fibroblasts in the breast tumor microenvironment.
- Cancer-Associated Fibroblasts (CAFs) Signature: The profound upregulation of numerous surface markers in Fibroblasts from primary tumor samples strongly points towards the activation and proliferation of Cancer-Associated Fibroblasts (CAFs). CAFs are a key component of the tumor stroma, known for their critical involvement in tumor growth, invasion, metastasis, angiogenesis, and immune suppression.
Key CAF-associated Surface Markers:
- FAP (Fibroblast Activation Protein): As highlighted by its high expression, FAP is a canonical marker for activated fibroblasts and CAFs across various solid tumors. It plays roles in extracellular matrix (ECM) remodeling, epithelial-mesenchymal transition, and immunosuppression GeneCards: FAP.
- CD276 (B7-H3): This immune checkpoint molecule is expressed on CAFs and contributes to the immunosuppressive environment within tumors, potentially by inhibiting T-cell function GeneCards: CD276.
- MMP14 (Matrix Metalloproteinase 14): Also known as MT1-MMP, this membrane-bound enzyme is crucial for degrading ECM components, facilitating tumor cell invasion and metastasis GeneCards: MMP14.
- GPNMB (Glycoprotein Non-Metastatic Melanoma Protein B): Often associated with cell adhesion, migration, and immune modulation, its upregulation in CAFs suggests a role in aggressive tumor phenotypes GeneCards: GPNMB.
- SDC2 (Syndecan-2): A cell surface proteoglycan involved in cell-matrix interactions and growth factor signaling, SDC2 can promote tumor progression and metastasis when highly expressed in CAFs GeneCards: SDC2.
- NRP2 (Neuropilin 2): A co-receptor for various ligands, NRP2 is involved in angiogenesis, lymphangiogenesis, and neuronal guidance, often contributing to tumor progression and metastatic dissemination when expressed by CAFs GeneCards: NRP2.
- DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2): A receptor tyrosine kinase activated by collagen, DDR2 mediates cellular responses to ECM, contributing to CAF activation and tumor invasiveness GeneCards: DDR2.
- Implications of Heterogeneity: The observed patient-to-patient variability in CAF marker expression suggests that CAFs are not a monolithic population. Different CAF subtypes may exist, contributing distinctly to tumor progression, or patient-specific factors influence CAF activation states. This heterogeneity could have implications for patient stratification and treatment response.
Clinical or Translational Implications
The identification of these condition-specific surfaceome markers in Fibroblasts has significant clinical and translational potential.
- Therapeutic Targets for CAF Depletion/Reprogramming: Genes such as FAP, CD276, MMP14, GPNMB, NRP2, and DDR2, which are highly and specifically expressed on the surface of tumor-associated Fibroblasts, represent promising targets for therapeutic intervention. Targeting these surface proteins could enable:
- Direct depletion of CAFs: Using antibody-drug conjugates or CAR-T cell therapies against CAF-specific surface markers.
- Reprogramming CAFs: Modulating CAF functions to make them less protumorigenic.
- Inhibition of CAF-mediated pro-tumor pathways: Blocking the activity of enzymes like FAP or MMP14, or disrupting signaling via receptors like CD276, NRP2, or DDR2 PubMed Search: FAP fibroblast cancer therapy clinical trial.
- CD276 (B7-H3) is actively being explored as an immune checkpoint target, with several agents in clinical development PubMed Search: CD276 B7-H3 cancer therapy.
- Biomarkers for Diagnosis and Prognosis: These markers could serve as diagnostic or prognostic indicators for breast cancer progression. Their presence and expression levels in biopsy samples could help assess the extent of CAF activation, potentially correlating with tumor aggressiveness, risk of metastasis, or patient response to therapy.
- Experimental Validation and Drug Development: The identified markers warrant further experimental validation at the protein level using techniques such as flow cytometry or immunohistochemistry on clinical breast cancer samples. This would confirm their utility as bona fide surface markers and support their development as targets for novel anti-cancer therapies.
18. Differential Expression of Cell Cycle-Related Gene YWHAZ in Breast Epithelial Cells
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the differential gene expression of a pre-defined set of cell cycle-related genes between primary tumor and normal conditions, specifically within Epithelial cells (identified as the major disease-related cell type and tumor origin cell type in this dataset). The aim was to identify genes with statistically significant expression differences (p-value < 0.1 and absolute log2 Fold Change > 0.1) and visualize their expression patterns. The provided boxplot highlights the expression of YWHAZ, a key cell cycle regulator, showing its distribution across the two conditions.
Visual Summary
The boxplot displays the gene expression levels of YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta) in Epithelial cells, comparing primary_tumor and normal conditions.
- Expression Levels: YWHAZ shows a visibly higher expression in primary_tumor Epithelial cells compared to normal Epithelial cells. The median expression in primary_tumor is approximately 0.86, whereas in normal it is around 0.76.
- Statistical Significance: A highly significant difference in expression is observed between the two conditions, indicated by a p-value of p ≤ 0.001. This suggests that the observed upregulation of YWHAZ in primary tumor cells is not due to random chance.
- Distribution: Both conditions show some variability in YWHAZ expression, represented by the spread of the boxes and whiskers. The individual data points (black dots) indicate the expression mean for each sample within the respective condition, providing insight into the sample-level variability.
Biological Interpretation
The significant upregulation of YWHAZ in primary tumor Epithelial cells suggests its potential involvement in breast cancer progression, particularly through its role in cell cycle regulation.
- YWHAZ (14-3-3ζ) Function: YWHAZ is a member of the highly conserved 14-3-3 protein family, which plays crucial roles in various cellular processes, including cell cycle control, signal transduction, apoptosis, and cell growth [1]. Specifically, 14-3-3 proteins act as adaptors or scaffolds, binding to phosphorylated proteins to modulate their activity, localization, or stability.
- Role in Cell Cycle: In the context of the cell cycle, 14-3-3 proteins, including YWHAZ, can interact with key cell cycle regulators like CDC25 phosphatases, Wee1 kinase, and cyclin-dependent kinases (CDKs) to promote or inhibit cell cycle progression. For instance, they can sequester CDC25 in the cytoplasm, preventing premature entry into mitosis [2]. Dysregulation of such interactions can lead to uncontrolled cell proliferation.
- Context of Epithelial Cells and Breast Cancer: Given that Epithelial cells are the primary cells of origin for most breast cancers, the observed upregulation of YWHAZ in these cells within the tumor microenvironment is highly relevant. Increased YWHAZ expression could contribute to enhanced cell proliferation, evasion of apoptosis, and altered signaling pathways, all hallmarks of cancer [3].
Clinical or Translational Implications
The finding that YWHAZ is significantly overexpressed in primary breast tumor Epithelial cells opens several potential clinical and translational avenues:
- Biomarker Potential: YWHAZ could serve as a diagnostic or prognostic biomarker for breast cancer, particularly in distinguishing tumor tissue from normal tissue. Its overexpression might correlate with specific tumor subtypes or stages.
- Therapeutic Target: Given its involvement in cell cycle regulation and its increased expression in tumor cells, YWHAZ or its associated signaling pathways could be explored as potential therapeutic targets. Modulating YWHAZ activity might help to curb uncontrolled proliferation in breast cancer.
- Research Focus: Further research into the precise mechanisms by which YWHAZ contributes to breast cancer development and progression in Epithelial cells could reveal novel therapeutic strategies.
---
References:
- YWHAZ (14-3-3 zeta) gene information: GeneCards. https://www.genecards.org/cgi-bin/carddisp.pl?gene=YWHAZ
- 14-3-3 Proteins in Cell Cycle Regulation: PubMed search for "14-3-3 cell cycle regulation". https://pubmed.ncbi.nlm.nih.gov/?term=14-3-3+cell+cycle+regulation
- Role of YWHAZ in Cancer: PubMed search for "YWHAZ breast cancer proliferation". https://pubmed.ncbi.nlm.nih.gov/?term=YWHAZ+breast+cancer+proliferation
19. Gene Ontology (GSA) Analysis of Epithelial Cells in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents Gene Ontology (GO) enrichment results (using Gene Set Analysis, GSA) for epithelial cells, a key cell type in breast tissue and the identified tumor origin cell type. The analysis compares gene expression profiles in two distinct contexts:
- Diploid_vs_others: Epithelial cells classified as "Diploid" (likely representing less transformed or normal-like cells) versus all other epithelial cells.
- primary_tumor_vs_others: Epithelial cells from "primary_tumor" condition versus all other conditions (presumably normal tissue epithelial cells).
The bar plots visualize the most significantly enriched GO terms, ranked by their statistical significance (-log(p-val) and -log(q-val)). These enriched terms highlight the biological processes and pathways that are differentially active in the specified comparison groups within the epithelial cell population.
Visual Summary
The two bar plots display the top significantly enriched Gene Ontology terms. Each plot consists of two panels: one showing -log(p-val) and the other showing -log(q-val) for each term. Higher values indicate greater statistical significance.
GSA for Epithelial cell: Diploid_vs_others
This plot shows terms enriched in diploid epithelial cells compared to non-diploid (likely aneuploid) epithelial cells.
Highly significant terms (high -log(p-val) and -log(q-val)) include
"Coronavirus disease"
"Focal adhesion"
"Ribosome biogenesis in eukaryotes"
"Epstein-Barr virus infection"
"Kaposi sarcoma-associated herpesvirus infection"
"Ribosome"
"TNF signaling pathway"
"Proteoglycans in cancer"
"Cellular senescence"
"Pathways in cancer"
- Several terms relate to viral infections, ribosome function, and fundamental cellular processes like focal adhesion and senescence, alongside general cancer pathways.
GSA for Epithelial cell: primary_tumor_vs_others
This plot shows terms enriched in epithelial cells from primary tumors compared to epithelial cells from normal tissue.
Highly significant terms (high -log(p-val) and -log(q-val)) include
"Thermogenesis"
"Oxidative phosphorylation"
"Huntington disease"
"Parkinson disease"
"Prion disease"
"Non-alcoholic fatty liver disease"
"Alzheimer disease"
"Diabetic cardiomyopathy"
"Pathways of neurodegeneration"
"Amyotrophic lateral sclerosis"
"Endocytosis"
"Protein processing in endoplasmic reticulum"
"Lysosome"
"Ubiquitin mediated proteolysis"
- Many of the top terms here are associated with metabolic processes (thermogenesis, oxidative phosphorylation, fatty liver disease) and protein homeostasis/stress responses (endoplasmic reticulum, lysosome, ubiquitination). A notable number of terms are related to neurodegenerative diseases, which often points to fundamental cellular stress, proteotoxicity, or mitochondrial dysfunction rather than primary neuronal disease in a breast cancer context.
Biological Interpretation
Epithelial Cells: Diploid vs. Other Ploidy States
The enrichment of terms like "Focal adhesion" and "Ribosome biogenesis" in diploid epithelial cells suggests active baseline cellular functions related to cell structure, adhesion, and protein synthesis. The presence of "Cellular senescence" and "Pathways in cancer" in this context could indicate that diploid epithelial cells, especially if they are adjacent to tumor regions or under oncogenic stress, might be engaging in tumor-suppressive mechanisms or early cellular responses to transformation. "TNF signaling pathway" and pathways related to various viral infections (e.g., Epstein-Barr virus, Human papillomavirus) might reflect either general immune responses present in the tissue or a specific host-response pattern in these less transformed cells, potentially against oncogenic viruses known to be implicated in some cancers. The "p53 signaling pathway" and "NF-kappa B signaling pathway" are critical regulators of cell cycle, apoptosis, and inflammation, which are active in maintaining cellular homeostasis or initiating stress responses.
Epithelial Cells: Primary Tumor vs. Normal Tissue
Epithelial cells from primary tumors exhibit a distinct biological signature compared to normal epithelial cells. The most prominent enrichments point towards significant metabolic reprogramming and cellular stress responses, characteristic hallmarks of cancer cells.
- Metabolic Reprogramming: "Thermogenesis" and "Oxidative phosphorylation" suggest altered energy metabolism. While oxidative phosphorylation is a key energy source, its dysregulation or increased activity can be observed in cancer cells adapting to new metabolic demands, potentially reflecting an increased reliance on mitochondrial function in certain tumor contexts rather than a pure glycolytic switch (Warburg effect). "Non-alcoholic fatty liver disease" and "Diabetic cardiomyopathy" terms, though related to systemic metabolic diseases, often signify perturbed lipid metabolism and glucose homeostasis, which are common features of cancer cell metabolism PubMed Search: Cancer metabolism review.
- Protein Homeostasis and Stress Response: Enrichment in "Protein processing in endoplasmic reticulum," "Lysosome," and "Ubiquitin mediated proteolysis" indicates significant activation of pathways dealing with protein synthesis, folding, degradation, and cellular waste management. Cancer cells often experience high metabolic and proliferative stress, leading to increased protein misfolding and activation of unfolded protein response (UPR) and ER stress pathways. Lysosomal activity and proteasome pathways are crucial for cell survival and adaptation under these stressful conditions.
- Cellular Stress and Neurodegeneration-like Signatures: The repeated appearance of neurodegenerative disease terms (e.g., "Huntington disease," "Parkinson disease," "Alzheimer disease," "Amyotrophic lateral sclerosis," "Prion disease") is noteworthy. In a cancer context, these terms are typically interpreted as indicators of severe cellular stress, proteotoxicity, mitochondrial dysfunction, and apoptosis signaling, rather than a direct link to neurological disease. These pathways often share common molecular mechanisms of protein aggregation, oxidative stress, and impaired cellular clearance, which are also relevant to cancer pathology and progression PubMed Search: Cancer neurodegeneration protein aggregation.
- Key Oncogenic Pathways: Other enriched terms like "mTOR signaling pathway" and "AMPK signaling pathway" are central regulators of cell growth, metabolism, and autophagy, frequently dysregulated in cancer GeneCards: mTOR.
In summary, diploid epithelial cells appear to be engaging in basal maintenance, stress responses, and potentially early tumor-suppressive mechanisms. In contrast, primary tumor epithelial cells exhibit profound metabolic shifts, heightened protein processing and degradation, and widespread cellular stress responses, consistent with their high proliferative rate and adaptation to the tumor microenvironment.
Clinical or Translational Implications
The distinct pathway enrichments in primary tumor epithelial cells offer potential avenues for therapeutic intervention and biomarker discovery in breast cancer:
- Metabolic Targeting: The significant enrichment of "Thermogenesis" and "Oxidative phosphorylation" suggests that targeting specific metabolic pathways in breast cancer epithelial cells could be a viable therapeutic strategy. Inhibitors of mitochondrial respiration or enzymes involved in specific metabolic branches could selectively impair tumor cell survival PubMed Search: Breast cancer metabolic targeting.
- Stress Response Modulation: The activation of protein processing pathways (ER, lysosome, ubiquitination) highlights the vulnerability of cancer cells to stressors that disrupt protein homeostasis. Modulating these pathways (e.g., proteasome inhibitors, ER stress modulators) could be effective, building on established cancer therapies like proteasome inhibitors in multiple myeloma UniProt: Proteasome.
- Targeting Oncogenic Signaling: The presence of "mTOR signaling pathway" enrichment reinforces its role as a key therapeutic target in cancer. Drugs targeting mTOR are already in clinical use or trials for various cancers, including breast cancer GeneCards: mTOR. Further investigation into the specific branches of mTOR signaling active in these cells could refine treatment strategies.
- Biomarker Identification: Genes within these significantly enriched pathways could serve as diagnostic or prognostic biomarkers for breast cancer, particularly in distinguishing tumor epithelial cells from normal ones, or in identifying specific metabolic phenotypes that may correlate with treatment response or resistance.
Understanding these context-specific pathway activations provides valuable insight into the underlying biology of breast cancer progression and potential therapeutic vulnerabilities.
20. Gene Set Enrichment Analysis (GSEA) of Breast Tissue Cell Types in Primary Tumor vs. Normal Conditions
[Analysis Visualization Results]...
Analysis Overview
This analysis utilizes Gene Set Enrichment Analysis (GSEA) to identify enriched or depleted biological pathways across key major cell types (Endothelial cell, Epithelial cell, Fibroblast, ILC, Macrophage, Smooth muscle cell) in breast tissue. The comparisons include cells from normal vs. others conditions, and primary_tumor vs. others conditions. For Epithelial cells, an additional comparison was performed for Diploid cells vs. others, providing insight into the role of ploidy. The dot plot visualizes the Normalized Enrichment Score (NES) and statistical significance (-log(p-val)) for 80 selected gene sets, highlighting significant shifts in cellular biology within the tumor microenvironment.
Visual Summary
The dot plot effectively displays the GSEA results, with cell type and comparison conditions on the X-axis and biological pathways (gene sets) on the Y-axis.
- Dot Color (NES): A color gradient from red to blue indicates the Normalized Enrichment Score (NES). Red signifies positive enrichment (pathway generally upregulated) in the 'test' condition compared to 'others', while blue indicates negative enrichment (pathway generally downregulated). A cutoff of NES > 1 or NES < -1 was applied for significant enrichments.
- Dot Size (-log(p-val)): The size of each dot corresponds to the negative logarithm of the adjusted p-value. Larger dots represent more statistically significant enrichments or depletions (p-val < 0.05).
- Overall Pattern: A prominent pattern of red-colored (enriched) pathways is observed across most cell types in primary_tumor_vs_others comparisons, indicating widespread activation of tumor-associated biological processes. Conversely, normal_vs_others and Epithelial cell: Diploid_vs_others comparisons often show blue-colored (depleted) dots for these same pathways, or enrichment of general cellular maintenance pathways.
Biological Interpretation
Widespread Metabolic Reprogramming in the Tumor Microenvironment
A striking and consistent finding across almost all examined cell types (Endothelial, Epithelial, Fibroblast, ILC, Macrophage, Smooth muscle cell) in primary_tumor_vs_others comparisons is the strong enrichment of metabolic pathways such as Glycolysis / Gluconeogenesis and Pyruvate metabolism. This indicates a systemic shift towards aerobic glycolysis, often referred to as the Warburg effect, which provides energy and building blocks for rapid proliferation not just in cancer cells but also in associated stromal and immune cells. This metabolic reprogramming is a hallmark of cancer and profoundly influences the tumor microenvironment.
- Reference: PubMed search: Warburg effect tumor microenvironment
Enhanced ECM Remodeling and Cell Adhesion
Pathways related to extracellular matrix (ECM) interaction and cell adhesion, specifically ECM-receptor interaction and Focal adhesion, are significantly enriched in Endothelial cells, Epithelial cells, Fibroblasts, Macrophages, and Smooth muscle cells within primary_tumor_vs_others. This highlights the extensive remodeling of the tumor microenvironment, which is critical for tumor growth, invasion, and metastasis in breast cancer.
Reference: PubMed search: ECM remodeling cancer metastasis
Activated Pro-Tumorigenic Signaling Pathways
Several crucial signaling pathways are consistently enriched in primary tumor samples across multiple cell types:
- VEGF signaling pathway: Enriched in Endothelial cells, Epithelial cells, Fibroblasts, ILCs, Macrophages, and Smooth muscle cells, reflecting increased angiogenesis, a critical process for tumor growth and survival.
- Wnt signaling pathway and cAMP signaling pathway: Show widespread enrichment, indicating their roles in promoting cell proliferation, survival, and differentiation within the tumor context.
- AGE-RAGE signaling pathway: Also broadly enriched, potentially contributing to inflammation and oxidative stress that fuel tumor progression.
- Pathways in cancer and breast cancer-specific pathways are highly enriched in primary tumor epithelial cells, confirming their malignant transformation.
Functional Reprogramming of Stromal and Immune Cells
- Fibroblasts (CAFs): In primary_tumor_vs_others, fibroblasts show strong enrichment in ECM remodeling, metabolic, and pro-angiogenic pathways, consistent with their well-established role as Cancer-Associated Fibroblasts (CAFs) that support tumor growth and invasion.
- Macrophages (TAMs): primary_tumor_vs_others macrophages display robust enrichment in cancer-associated pathways, metabolic reprogramming, and depletion of classical immune functions like Phagosome. This suggests a shift towards a tumor-supportive, M2-like phenotype (Tumor-Associated Macrophages, TAMs) in the breast tumor microenvironment.
- Endothelial cells: Tumor-associated endothelial cells show strong enrichment of angiogenesis-related and metabolic pathways, indicative of their active role in forming tumor vasculature.
- ILCs and Smooth Muscle Cells: These cell types also exhibit enrichment in metabolic and cancer-related pathways in primary_tumor_vs_others, suggesting their active participation and functional alteration within the tumor microenvironment.
Distinct Biology of Diploid Epithelial Cells
The comparison of Epithelial cell: Diploid_vs_others versus Epithelial cell: primary_tumor_vs_others reveals critical differences:
- Diploid epithelial cells (even within tumor samples) show enrichment for fundamental cellular maintenance and metabolic pathways such as Aminoacyl-tRNA biosynthesis, DNA replication, Oxidative phosphorylation, Peroxisome, Proteasome, RNA degradation, RNA polymerase. This profile closely resembles normal_vs_others epithelial cells, suggesting that diploid cells may represent residual normal cells or a less aggressive subpopulation with preserved cellular homeostasis.
- Conversely, primary_tumor_vs_others epithelial cells (which would largely encompass aneuploid tumor cells) exhibit a depletion of these 'normal' maintenance pathways, accompanied by a strong enrichment of pro-tumorigenic and metabolic reprogramming pathways mentioned above. This highlights the distinct molecular and functional landscape of transformed epithelial cells.
Clinical or Translational Implications
- Biomarker Discovery: The consistently enriched pathways (e.g., VEGF signaling, Wnt signaling, metabolic pathways, ECM interaction) across multiple cell types in primary tumors represent a rich source for potential diagnostic, prognostic, or predictive biomarkers in breast cancer.
- Therapeutic Targets: The observed widespread metabolic reprogramming (glycolysis) and activation of specific signaling pathways (VEGF, Wnt, AGE-RAGE) across cancer cells and the tumor microenvironment suggest that therapeutic strategies targeting these common vulnerabilities could have broad anti-tumor effects, influencing not only cancer cells but also their supportive stromal and immune components.
- Reference: PubMed search: metabolic targeting cancer therapy
- Tumor Microenvironment-Focused Therapies: The active and integrated roles of stromal (fibroblasts, endothelial cells, smooth muscle cells) and immune cells (macrophages, ILCs) in supporting tumor growth emphasize the importance of developing therapies that consider the entire tumor ecosystem, rather than focusing solely on cancer cells.
- Ploidy as a Prognostic Factor: The distinct pathway activities associated with Diploid versus primary_tumor epithelial cells underscore the potential of ploidy status as a significant indicator of cellular state and likely tumor aggressiveness. Further investigation into the fate and response to therapy of diploid tumor cells or co-existing normal cells within the tumor could inform personalized treatment strategies.
21. Discussion
The comprehensive single-cell analysis of breast tissue provides profound insights into the distinct cellular and molecular features of the primary tumor microenvironment compared to normal tissue. A cornerstone finding is the widespread genomic instability, evidenced by extensive aneuploidy, predominantly observed in epithelial cells within primary tumors. UMAP visualizations based on CNV estimates clearly segregate aneuploid epithelial cells from diploid counterparts and other cell types, strongly supporting their malignant nature and highlighting genomic alteration as a primary driver of cellular heterogeneity in cancer. Recurrent amplifications on chromosomes 1q, 8q, 11q, and 20q, including genes like *NFASC* and *EIF3E*, are consistent with known genomic aberrations in breast cancer, underscoring their potential role in tumorigenesis and validating the ploidy inference.
The cellular composition shifts dramatically in the primary tumor. Epithelial cells remain dominant, but a significant proportion of 'unassigned' cells in tumors may represent highly aberrant or novel malignant cell states. Fibroblasts are consistently abundant, indicative of an activated stromal compartment, while macrophages show a noticeable increase, pointing towards heightened immune cell infiltration. Within immune populations, T cell subsets are highly variable, with some tumors exhibiting increased cytotoxic T cells. Notably, both T follicular helper (Tfh) and regulatory T (Treg) cells are significantly elevated in primary tumors, while Lymphoid Tissue Inducer (LTI) cells are reduced. Macrophages in tumors show an increased proportion of M1 phenotypes, suggesting an anti-tumor inflammatory response, yet M2-like subsets remain prominent, implying a complex and often immunosuppressive immune landscape. This co-existence of M1 and M2 phenotypes in tumors, rather than a clear M2 dominance often reported, suggests a more nuanced, dynamic balance of macrophage polarization that could vary greatly between patients and within different tumor regions.
Cell-cell interaction (CCI) analyses reveal extensive reprogramming of intercellular communication within the tumor. A pervasive feature is the highly active extracellular matrix (ECM)-integrin signaling, primarily between cancer-associated fibroblasts (CAFs), endothelial cells, and epithelial cells, involving collagens (e.g., COL6A1/2/3, COL18A1) and fibronectin (FN1) with various integrin complexes. This indicates significant ECM remodeling and mechanotransduction driving tumor invasion and angiogenesis. Other critical pathways include robust pro-angiogenic signaling (PGF-FLT1, VEGF-VEGFR2) and active TGF-beta signaling, particularly originating from aneuploid epithelial cells and extensively involving fibroblasts and macrophages, which is known to promote immune suppression and desmoplasia. Epithelial cells from primary tumors also show upregulation of surface markers like ERBB3, CA12, ADAM15, and ALCAM, reflecting their transformed state, while tumor-associated macrophages (TAMs) express unique markers such as EREG, ITGB8, CXCR4, and MET. CAFs themselves acquire distinct surfaceome markers including FAP, CD276, and MMP14. The finding that YWHAZ, a cell cycle regulator, is significantly upregulated in tumor epithelial cells further highlights altered proliferative control.
Gene Ontology (GSA) and Gene Set Enrichment Analysis (GSEA) reinforce these findings, showing widespread metabolic reprogramming (glycolysis, pyruvate metabolism) across nearly all cell types in the primary tumor microenvironment, not just the malignant cells. This generalized metabolic shift, coupled with enriched ECM-receptor interaction, focal adhesion, and VEGF/Wnt signaling pathways, paints a picture of a highly collaborative and metabolically active ecosystem supporting tumor growth. The distinct biological profiles of diploid versus aneuploid epithelial cells, with diploid cells enriched for basic cellular maintenance and the primary tumor cells exhibiting profound metabolic shifts and stress responses, further delineates the molecular consequences of genomic instability.
Hypotheses:
- Aneuploid epithelial cells, through aberrant WNT and TGF-beta signaling, directly orchestrate the activation and ECM-remodeling functions of cancer-associated fibroblasts (CAFs), driving tumor invasion and metastasis.
- The observed increase in T follicular helper (Tfh) and regulatory T (Treg) cells, alongside specific pro-tumorigenic macrophage (TAM) populations characterized by markers like CXCR4 and EREG, collectively contribute to an immunosuppressive tumor microenvironment, enabling immune evasion.
- Widespread metabolic reprogramming, including enhanced glycolysis and pyruvate metabolism across tumor epithelial cells, fibroblasts, and macrophages, creates a synergistic metabolic landscape that fuels tumor growth and suppresses anti-tumor immunity.
- The reduction of Lymphoid Tissue Inducer (LTI) cells in primary tumors leads to impaired formation or functionality of tertiary lymphoid structures (TLS), diminishing local anti-tumor immune responses.
Potential therapeutic targets:
- TGF-beta pathway (e.g., TGFB1, TGF-beta receptors): TGF-beta signaling is a central driver of pro-tumorigenic processes in the breast cancer microenvironment, extensively mediating interactions between aneuploid epithelial cells, fibroblasts, and macrophages to promote immune evasion, fibrosis, and tumor progression. Evidence: CCI analyses (Sections 11, 13) show strong TGFB1/2/3 and TGF-beta receptor interactions across multiple cell types in primary tumors. GSEA (Section 20) indicates widespread enrichment of TGF-beta related pathways. Macrophage-epithelial interactions via TGFB ligands suggest potential M2-like macrophage polarization. Validation: Evaluate the efficacy of TGF-beta inhibitors (receptor kinases or ligand traps) in breast cancer preclinical models (e.g., PDX, organoids) to reduce tumor growth, metastasis, CAF activation (FAP, collagen deposition), and immune suppression (Treg/TAM modulation). Assess changes in target engagement via IHC/western blot.
- FAP (Fibroblast Activation Protein): FAP is a canonical surface marker highly and specifically expressed on activated Cancer-Associated Fibroblasts (CAFs), which are critical for ECM remodeling, immune suppression, and supporting tumor growth and invasion. Evidence: Fibroblast condition-specific markers (Section 17) show FAP as a top upregulated surfaceome marker in primary tumor fibroblasts. Validation: Develop or utilize FAP-targeting antibody-drug conjugates (ADCs) or CAR-T cell therapies in *in vivo* breast cancer models. Validate target specificity and anti-tumor efficacy, including reduction in tumor volume, metastasis, and changes in tumor stromal composition (e.g., collagen content, other CAF markers).
- ERBB3 (HER3): ERBB3 is a surface receptor specifically overexpressed on primary tumor epithelial cells, a key oncogenic driver in breast cancer, often associated with tumor growth, survival, and therapy resistance. Evidence: Epithelial cell condition-specific surfaceome markers (Section 15) clearly show ERBB3 as highly upregulated and specific to primary tumor epithelial cells. Validation: Test ERBB3-targeting agents (e.g., monoclonal antibodies, ADCs) in *in vitro* 3D cultures of patient-derived tumor epithelial cells and *in vivo* xenograft models. Assess impact on cell proliferation, survival, and sensitivity to standard-of-care therapies. Confirm ERBB3 protein expression in clinical samples via IHC.
- CXCR4: CXCR4 is a chemokine receptor highly expressed on tumor-associated macrophages and involved in fibroblast-fibroblast interactions, crucial for immune cell migration, tumor cell invasion, and creating an immunosuppressive/pro-metastatic microenvironment. Evidence: Macrophage condition-specific surfaceome markers (Section 16) show CXCR4 as a top upregulated marker in TAMs. CCI analysis (Section 12) identifies CXCL12-CXCR4 interactions particularly between fibroblasts and macrophages. Validation: Utilize CXCR4 antagonists in preclinical breast cancer models to evaluate their ability to reduce TAM and Treg infiltration, inhibit tumor cell invasion/metastasis, and enhance the efficacy of immunotherapies. Monitor changes in immune cell populations via flow cytometry from tumor biopsies.
- Integrin receptors (e.g., αVβ1, αVβ5, α5β1): Integrins are broadly involved in extensive ECM-receptor interactions and focal adhesion across epithelial, fibroblast, and endothelial cells in primary tumors, mediating tumor growth, invasion, angiogenesis, and resistance to therapy. Evidence: CCI analyses (Sections 11, 12, 14) consistently highlight diverse integrin complexes (e.g., FN1-integrin_a3b1, COL6A1-integrin_a1b1) as highly active, especially in primary tumor conditions and across tumor-stromal-endothelial cell interfaces. GSEA (Section 20) shows enrichment of 'ECM-receptor interaction' and 'Focal adhesion' pathways. Validation: Employ integrin-blocking antibodies or small molecule inhibitors (specific to αVβ1, αVβ5, α5β1) in *in vitro* assays for tumor cell adhesion, migration, and invasion on various ECM substrates. *In vivo*, assess their impact on primary tumor growth, angiogenesis (CD31 staining), and metastasis in relevant breast cancer models.
Follow-up validation ideas:
- Perform spatial transcriptomics or multiplexed immunostaining (e.g., CODEX, IMC) to validate the co-localization and direct interaction of aneuploid epithelial cells, CAFs (FAP+, ACTA2+), and immune cells (Tregs, TAMs) within tumor tissues, particularly focusing on WNT and TGF-beta ligand-receptor co-expression.
- Utilize *in vitro* co-culture models of tumor epithelial cells, fibroblasts, and macrophages, coupled with targeted perturbation assays (e.g., siRNA knockdown, small molecule inhibitors of WNT, TGF-beta, or CXCR4), to assess their impact on ECM deposition, cell migration, invasion, and immune cell polarization (e.g., flow cytometry for M1/M2 markers).
- Conduct metabolic tracing experiments (e.g., 13C-glucose/glutamine tracing) on sorted tumor epithelial cells, fibroblasts, and macrophages from both normal and tumor conditions to quantitatively validate the altered metabolic fluxes, particularly glycolysis and oxidative phosphorylation, identified by GSEA.
- Validate the functional impact of reduced LTI cells by comparing the presence and organization of tertiary lymphoid structures (TLS) in breast cancer patients with high versus low LTI cell proportions via immunohistochemistry. Perturbation of LTI cells in *in vivo* tumor models could assess its effect on anti-tumor immunity and tumor progression.
Limitations:
This report is based on single-cell RNA-sequencing data, which provides transcriptomic snapshots. While CNV estimates are included, they are inferred from RNA-seq and may not fully capture the complexity of genomic alterations compared to dedicated genomic assays. Cell-cell interaction predictions are computational and require experimental validation to confirm functional relevance. The 'unassigned' cell populations in tumor samples warrant further investigation. The dataset represents human breast tissue; however, inter-patient heterogeneity, as observed, suggests that generalizability to all breast cancer subtypes or patients may require broader validation cohorts. Causality of observed associations cannot be definitively established from this correlative analysis.
22. Query List
- Show UMAPs including condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns and save.
- Show expression levels of CD3D, CD4, CD8A, CD79A, MS4A1, MZB1, CD14, LYZ, FBLN1, NOTCH3, EPCAM, MUC1, CD34 genes on UMAP along with minor cell type annotations. Set ncols=4 and save.
- Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
- Filter for tumor origin cells (Epithelial cell) and unassigned cells, group by sample, show CNV heatmap, and include a summary of significantly amplified copy number regions, then save.
- Show CNV patterns on UMAP, including major cell type, minor cell type, ploidy results, condition, and sample in 2 columns, then save.
- Show a population bar plot of minor cell types and save.
- Show a subset population bar plot for T cells and save.
- Show a subset population bar plot for Macrophages and save.
- For T cell subset populations, show a boxplot for statistically significant differences between conditions if any, and save. Determine ncols appropriately based on the total number of panels.
- Filter for tumor origin cells (Epithelial cell) and unassigned cells, show their ploidy population as a bar plot, and save.
- Show cell-cell interaction patterns per condition, including tumor origin cells (Epithelial cell), Fibroblast, Macrophage, and T cells. Select up to 80 cell-cell interactions for each condition and save.
- Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
- Filter for immune checkpoint and cell cycle pathway related genes, show cell-cell interactions for these genes, and save.
- For major immune and stromal cells, find statistically significant differences in cell-cell interactions between conditions and show them as a dot plot. Set max_n_items_per_group = 25 and save.
- Show the condition-specific markers for tumor-origin cells (Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
- Extract condition-specific markers for Macrophages, show them as a dot plot, and save. Only show surfaceome markers, up to 50 per condition.
- Extract condition-specific markers for Fibroblasts, show them as a dot plot, and save. Only show surfaceome markers, up to 50 per condition.
- For cell cycle pathway related genes, select genes with statistically significant expression differences between conditions in major disease-related cells (Epithelial cell), show them as a boxplot, and save. Set max_n_items_to_plot = 24, and determine ncols such that the aspect ratio of width to height is approximately 2x3 based on the total number of panels.
- Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
- Show a dot plot of Gene Set Enrichment Analysis results for major cell types (Endothelial cell, Epithelial cell, Fibroblast, ILC, Macrophage, Smooth muscle cell). Set color map to RdBu_r and n_pws_to_show = 80, then save.



















